

suPAR PubMed Publications and links
Organ and Disease grouped



Organ and Disease Groups:

1. Acute Care and Emergency Medicine
2. Autoimmune and Deficiency Conditions
3. Brain and Neurology
4. Bone
5. Cancers
6. Cardiac conditions and Cardiovascular Diseases
7. Diabetes
8. Exercise and Physical Conditions
9. Gastric Conditions
10. General Population Studies
11. Hepatic Conditions
12. Infectious Diseases and Inflammation
13. Mental Diseases
14. Nephrology Conditions
15. Pulmonary Conditions
16. Sepsis and SIRS conditions
17. suPAR outside disease groups
18. Traume
19. Transplantation

1. Acute Care and Emergency Medicine

[suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients.](#)

Meyer J, Alstrup M, Rasmussen LJH, Schultz M, Ladelund S, Haupt TH, Tingleff J, Iversen K, Eugen-Olsen J. Scand J Trauma Resusc Emerg Med. 2018 Feb 1

[Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD.](#)

AboEl-Magd GH, Mabrouk MM. J Bras Pneumol. 2018 Jan-Feb

[A high-protein diet during hospitalization is associated with an accelerated decrease in soluble urokinase plasminogen activator receptor levels in acutely ill elderly medical patients with SIRS.](#)

Tavenier J, Haupt TH, Andersen AL, Buhl SF, Langkilde A, Andersen JR, Jensen JB, Pedersen MM, Petersen J, Andersen O. Nutr Res. 2017 May;41:56-64.

[How inflammation underlies physical and organ function in acutely admitted older medical patients.](#)

Klausen HH, Bodilsen AC, Petersen J, Bandholm T, Haupt T, Sivertsen DM, Andersen O. Mech Ageing Dev. 2017 Apr 22;164:67-75.

[Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster randomized interventional trial.](#)

Sandø A, Schultz M, Eugen-Olsen J, Rasmussen LS, Køber L, Kjølner E, Jensen BN, Ravn L, Lange T, Iversen K. Scand J Trauma Resusc Emerg Med. 2016 Aug 5;24:100 - **suPARnostic®**

[Soluble urokinase plasminogen activator receptor \(suPAR\) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.](#)

Rasmussen LJ, Ladelund S, Haupt TH, Ellekilde G, Poulsen JH, Iversen K, Eugen-Olsen J, Andersen O. Emerg Med J. 2016 Sep 2 - **suPARnostic®**

[suPAR as a biomarker for risk of readmission and mortality in the acute medical setting.](#)

Nayak RK, Allingstrup M, Phanareth K, Kofoed-Enevoldsen A. Dan Med J. 2015 Oct;62(10). pii: A5146. – **suPARnostic®**

[The predictive value of soluble urokinase plasminogen activator receptor \(SuPAR\) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.](#)

Ville J, Jukka V, Ville P, Jouni K, Tero V, Marjaana T, Heini H, Ari A, Seppo H, Outi K, Anne K, Jyrki T; The FINNRESUSCI LAB STUDY GROUP. Resuscitation. 2014 Sep 2. pii: S0300-9572(14)00719-9. – **suPARnostic®**

[Biomarkers and molecular analysis to improve bloodstream infection diagnostics in an emergency care unit.](#)

Loonen AJ, de Jager CP, Tosserams J, Kusters R, Hilbink M, Wever PC, van den Brule AJ. PLoS One. 2014 Jan 27;9(1):e87315..– **suPARnostic®**

[Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission.](#)

Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibañez M. Intensive Care Med. 2013 Feb;46(3):225-9. - **suPARnostic®**

[Soluble Urokinase Plasminogen Activator Receptor for Risk Prediction in Patients Admitted with Acute Chest Pain.](#)

Lyngbæk S, Andersson C, Marott JL, Møller DV, Christiansen M, Iversen KK, Clemmensen P, Eugen-Olsen J, Hansen PR, Jeppesen JL.

Clin Chem. 2013. Nov;59(11):1621-9 - **suPARnostic®**

[Diagnostic accuracy of soluble urokinase plasminogen activator receptor \(suPAR\) for prediction of bacteremia in patients with systemic inflammatory response syndrome.](#)

Hoenigl M, Raggam RB, Wagner J, Valentin T, Leitner E, Seeber K, Zollner-Schwetz I, Krammer W, Prüller F, Grisold AJ, Krause R.

Clin Biochem. 2012 Nov 13. 2013 Feb;46(3):225-9– **suPARnostic®**

[Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study.](#)

Haupt TH, Petersen J, Ellekilde G, Klausen HH, Thorball CW, Eugen-Olsen J, Andersen O.

Crit Care. 2012 Jul 23;16(4):R130. - **suPARnostic®**

[Risk stratification and triage in the emergency department: has this become 'suPAR' easy?](#)

Koch A, Tacke F.

J Intern Med. 2012 Jul. ;272(3):243-6.– **suPARnostic®**

[Soluble urokinase-type plasminogen activator receptor \(suPAR\) in patients with suspected infection in the emergency room: a prospective cohort study.](#)

Uusitalo-Seppälä R, Huttunen R, Tarkka M, Aittoniemi J, Koskinen P, Leino A, Vahlberg T, Rintala EM.

J Intern Med. 2012 Jul 3 272(3):247-56.- **suPARnostic®**

2. Autoimmune and Deficiency Conditions

[uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action.](#)

Dinesh P, Rasool M. Pharmacol Res. 2018 May 31

[IFN- \$\gamma\$, CXCL16, uPAR: potential biomarkers for systemic lupus erythematosus.](#)

Wen S, He F, Zhu X, Yuan S, Liu H, Sun L.Clin Exp Rheumatol. 2017 Jun 16. [Epub ahead of print]

[Untreated Psoriasis Impairs Male Fertility: A Case-Control Study.](#)

Caldarola G, Milardi D, Grande G, Quercia A, Baroni S, Morelli R, Marana R, Pontecorvi A, De Simone C, Peris K. 2017

[Plasma-soluble urokinase plasminogen activator receptor \(suPAR\) levels in Behçet's disease and correlation with disease activity.](#)

Saylam Kurtipek G, Kesli R, Tuncez Akyurek F, Akyurek F, Ataseven A, Terzi Y. Int J Rheum Dis. 2016 May 12.

- **suPARnostic®**

[The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor \(suPAR\) Levels in Autoimmune Connective Tissue Disorders.](#)

Vasarhelyi B, Toldi G, Balog A. EJIFCC. 2016 Apr 20;27(2):122-9. - **suPARnostic®**

[Plasma-soluble urokinase plasminogen activator receptor \(suPAR\) levels in psoriasis patients and correlation with disease severity.](#)

Kurtipek GS, Kesli R, Tunçez Akyürek F, Akyüret F, Terzi Y.
Acta Dermatovenerol Alp Pannonica Adriat. 2015 Dec;24(4):73-5.

[Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients.](#)

Geboers DG, de Beer FM, Tuip-de Boer AM, van der Poll T, Horn J, Cremer OL, Bonten MJ, Ong DS, Schultz MJ, Bos LD.
Intensive Care Med. 2015 Jul;41(7):1281-90.– suPARnostic®

[Soluble urokinase plasminogen activator receptor-A valuable biomarker in systemic lupus erythematosus?](#)

Enocsson H, Sjöwall C, Wetterö J.
Clin Chim Acta. 2015 Feb 19. pii: S0009-8981(15)00103-5. Review.

[Extracellular Matrix Biomarker, Fibulin-1 and Its Association with Soluble uPAR in a Bi-ethnic South African Population: The SAfrEIC Study.](#)

du Plooy CS, Kruger R, Huisman HW, Rasmussen LM, Eugen-Olsen J, Schutte AE.
Heart Lung Circ. 2015 Mar;24(3):298-305. - suPARnostic®

[Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.](#)

Enocsson H, Wetterö J, Skogh T, Sjöwall C.
Transl Res. 2013 Aug 1. 162(5):287-96. - suPARnostic®

[The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome](#)

Yilmaz G, Köksal I, Karahan SC, Mentese A.
Clin Biochem. 2011 Oct;44(14-15):1227-30. - suPARnostic®

[Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy.](#)

Lönnkvist MH, Theodorsson E, Holst M, Ljung T, Hellström PM.
Scand J Gastroenterol. 2010 Apr;46(4):420-7.– suPARnostic®

[Release of the soluble urokinase-type plasminogen activator receptor \(suPAR\) by activated neutrophils in rheumatoid arthritis.](#)

Pliyev BK, Menshikov MY.
Inflammation. 2010 Feb;33(1):1-9.

[Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency.](#)

Fevang B, Eugen-Olsen J, Yndestad A, Brosstad F, Beiske K, Aukrust P, Frøland SS.
Clin Immunol. 2009 Jun;131(3):438-46.– suPARnostic®

[Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B \(MMP-9\) contribute to inflammation in gouty arthritis of the knee.](#)

Chu SC, Yang SF, Lue KH, Hsieh YS, Hsiao TY, Lu KH.
J Rheumatol. 2006 Feb;33(2):311-7.

[Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.](#)

Slot O, Br nner N, Locht H, Oxholm P, Stephens RW.
Ann Rheum Dis. 1999 Aug;58(8):488-92.

3. Brain and neurology

[Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Is Not Associated with Neurological Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage.](#)

Kiiski H, Jalkanen V, Ala-Peijari M, H m l inen M, Moilanen E, Peltola J, Tenhunen J. Front Neurol. 2017 Apr 18;8:144.

[Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants.](#)

Haastруп E, Grau K, Eugen-Olsen J, Thorball C, Kessing LV, Ullum H.
PLoS One. 2014 Oct 20;9(10):e110555. - **suPARnostic**[®]

[Soluble urokinase receptor \(uPAR, CD 87\) is present in serum and cerebrospinal fluid in patients with neurologic diseases.](#) Garcia-Monco JC, Coleman JL, Benach JL.

J Neuroimmunol. 2002 Aug;129(1-2):216-23.

4. Bone

[Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release.](#)

Vaschetto R, Navalesi P, Clemente N, Boggio E, Valsecchi S, Olivieri C, Soluri MF, Kroumova V, Fonio P, Dinatale C, Borr  S, Fortina G, Umberto D, Della Corte F, Chiocchetti A.
Minerva Anesthesiol. 2015 Feb;81(2):157-65.

5. Cancers

[Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and \$\beta\$ 1 Integrin in Patients with Hodgkin's Lymphoma.](#)

Kouhpayeh S, Andalib A, Gharagozloo M, Sanei MH, Esmail N, Maracy MR. Adv Biomed Res. 2017 Aug 28

[Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.](#)

Guo H, Zhou LX, Ma H, Liu B, Cheng J, Ma YY, Zhao L. Oncol Lett. 2017 Jul

[Cleavage of the urokinase receptor \(uPAR\) on oral cancer cells: regulation by transforming growth factor - \$\beta\$ 1 \(TGF- \$\beta\$ 1\) and potential effects on migration and invasion.](#)

Magnussen SN, Hadler-Olsen E, Costea DE, Berg E, Jacobsen CC, Mortensen B, Salo T, Martinez-Zubiaurre I, Winberg JO, Uhlin-Hansen L, Svineng G. BMC Cancer. 2017 May 19

[Prognostic Role of Circulating Soluble uPAR in Various Cancers: a Systematic Review and Meta-Analysis.](#)

Liu KL, Fan JH, Wu J. Clin Lab. 2017 May 1

[Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer.](#)

Rasmussen LJH, Schultz M, Gaardsting A, Ladelund S, Garred P, Iversen K, Eugen-Olsen J, Helms M, David KP, Kjaer A, Lebech AM, Kronborg G. *Int J Cancer*. 2017 Jul 1;141(1):191-199.

[Involvement of urokinase receptor in the cross-talk between human hematopoietic stem cells and bone marrow microenvironment.](#)

Selleri C, Montuori N, Salvati A, Serio B, Pesapane A, Ricci P, Gorrasi A, Li Santi A, Hoyer-Hansen G, Ragno P. *Oncotarget*. 2016 Aug 8

[A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.](#)

Leandersson P, Kalapotharakos G, Henic E, Borgfeldt H, Petzold M, Høyer-Hansen G, Borgfeldt C. *Anticancer Res*. 2016 Mar;36(3):957-65.

[Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.](#)

Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A. *BMC Cancer*. 2015 Jul 1;15:492.

[The Prognostic Significance Of Soluble Urokinase Plasminogen Activator Receptor In Acute Myeloid Leukemia.](#)

Erkut N, Mentese A, Ozbas HM, Ermantas N, Sumer A, Orem A, Sonmez M. *Turk J Haematol*. 2015 Aug 6.

[Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis.](#)

Shen J, Wang Q, Wang J, Su GH, Wang J, Guo S, Liu YA, Wu Z, Liu RF, Li X, Guo XJ, Cao J, Zhang YH, Wang ZY. *Oncol Lett*. 2015 Oct;10(4):2403-2409.

[Soluble uPAR is released selectively by glioblastoma cells that express EGF receptor variant III and promotes tumor cell migration and invasion.](#)

Gilder AS, Jones KA, Hu J, Wang L, Chen CC, Carter BS, Gonias SL. *J Biol Chem*. 2015 Apr 2. pii: jbc.M115.637488.

[The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.](#)

Wach S, Al-Janabi O, Weigelt K, Fischer K, Greither T, Marcou M, Theil G, Nolte E, Holzhausen HJ, Stöhr R, Huppert V, Hartmann A, Fornara P, Wullich B, Taubert H. *Int J Cancer*. 2015 Mar 6. 5;137(6):1406-16

[Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma.](#)

Chounta A, Ellinas C, Tzanetakou V, Pliarhopoulou F, Mplani V, Oikonomou A, Leventogiannis K, Giamarellos-Bourboulis EJ. *Liver Int*. 2015 Feb;35(2):601-7. **suPARnostic®**

[Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.](#)

Tarpgaard LS, Christensen IJ, Høyer-Hansen G, Lund IK, Guren TK, Glimelius B, Sorbye H, Tveit KM, Nielsen HJ, Moreira JM, Pfeiffer P, Brünner N.
Int J Cancer. 2015 Feb 9.

[Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease-- preliminary report.](#)

Usnarska-Zubkiewicz L, Strutyńska-Karpińska M, Zubkiewicz-Kucharska A, Zarębski P, Grabowski K.
Adv Clin Exp Med. 2014 Nov-Dec;23(6):959-67.

[Heat shock proteins HSP70 and MRJ cooperatively regulate cell adhesion and migration through urokinase receptor.](#)

Lin Y, Peng N, Zhuang H, Zhang D, Wang Y, Hua ZC.
BMC Cancer. 2014 Aug 30;14:639.

[Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.](#)

Al-Janabi O, Taubert H, Lohse-Fischer A, Fröhner M, Wach S, Stöhr R, Keck B, Burger M, Wieland W, Erdmann K, Wirth MP, Wullich B, Baretton G, Magdolen V, Kotzsch M, Füssel S.
Biomed Res Int. 2014;2014:972587.

[Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.](#)

Fujimura K, Ebinuma H, Fukamachi I, Ohwada C, Kawaguchi T, Shimizu N, Takeuchi M, Sakaida E, Jiang M, Nakaseko C, Bujo H.
Clin Chim Acta. 2014 Mar 20;430:48-54.

[The significance of serum urokinase plasminogen activation receptor \(suPAR\) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.](#)

Kaya S, Köksal I, Menteşe A, Sönmez M, Sümer A, Yıldırım SS, Yılmaz G.
Int J Infect Dis. 2013 Jun 3. 17(11):e1056-9. - **suPARnostic®**

[Transmission of Angiosarcomas From a Common Multiorgan Donor to Four Transplant Recipients.](#)

Thoning J, Liu Y, Bistrup C, Thomassen A, Borst C, Marcussen N, Tepel M.
Am J Transplant. 2012 Oct 24.

[Elevated urinary levels of urokinase-type plasminogen activator receptor \(uPAR\) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.](#)

Sorio C, Mafficini A, Furlan F, Barbi S, Bonora A, Brocco G, Blasi F, Talamini G, Bassi C, Scarpa A.
BMC Cancer. 2011 Oct 14;11:448.

[Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals.](#)

Langkilde AA, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, Jeppesen J, Eugen-Olsen J.
Cancer Epidemiol Biomarkers Prev. 2011 Jan 14. – **suPARnostic®**

[Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.](#)

Kjellman A, Akre O, Gustafsson O, Høyer-Hansen G, Lilja H, Norming U, Piironen T, Törnblom M.
J Intern Med. 2010 Sep 1;269(3):299-305.

[Preoperative concentrations of suPAR and MBL proteins are associated with the development of pneumonia after elective surgery for colorectal cancer.](#)

Svendsen MN, Ytting H, Brünner N, Nielsen HJ, Christensen IJ.
Surg Infect (Larchmt). 2006 Oct;7(5):463-71.

[Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer.](#)

Cobos E, Jumper C, Lox C.
Clin Appl Thromb Hemost. 2003 Jul;9(3):241-6.

[Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer.](#)

Cobos E, Jumper C, Lox C.
Clin Appl Thromb Hemost. 2003 Jul;9(3):241-6.

[Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.](#)

Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Høyer-Hansen G, Smith K, Brünner N, Harris AL.
Clin Cancer Res. 2002 May;8(5):1132-41.

[Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.](#)

Fernebro E, Madsen RR, Fernö M, Brünner N, Bendahl P, Christensen IJ, Johnson A, Nilbert M.
Eur J Cancer. 2001 Mar;37(4):486-91.

[Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.](#)

Mustjoki S, Sidenius N, Sier CF, Blasi F, Elonen E, Alitalo R, Vaheri A.
Cancer Res. 2000 Dec 15;60(24):7126-32.

[Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance.](#)

Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brünner N, Blasi F.
Lab Invest. 1999 Jun;79(6):717-22.

[The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.](#)

Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F.
Cancer Res. 1998 May 1;58(9):1843-9.

[ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.](#)

Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Høyer-Hansen G, Rønne E, Dybkjaer E, Danø K, Brünner N. *Clin Chem.* 1997 Oct;43(10):1868-76.

6. Cardiac conditions and Cardiovascular Diseases

[Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.](#)

Jirak P, Fejzic D, Paar V, Wernly B, Pistulli R, Rohm I, Jung C, Hoppe UC, Schulze PC, Lichtenauer M, Yilmaz A, Kretzschmar D. *Acta Pharmacol Sin.* 2017 Dec 14

[SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis.](#)

Hodges GW, Bang CN, Eugen-Olsen J, Olsen MH, Boman K, Ray S, Kesäniemi AY, Jeppesen JL, Wachtell K. *Open Heart.* 2018 Jan 13

[Vascular inflammation: A call for a specific and sensitive biomarker?](#)

Bellasi A, Di Lullo L, Di Iorio B. *Atherosclerosis.* 2018 Apr

[Prognostic value of suPAR and hs-CRP on cardiovascular disease.](#)

Diederichsen MZ, Diederichsen SZ, Mickley H, Steffensen FH, Lambrechtsen J, Sand NPR, Christensen KL, Olsen MH, Diederichsen A, Grønhøj MH. *Atherosclerosis.* 2018 Apr

[Analysis of novel cardiovascular biomarkers in patients with peripheral artery disease \(PAD\).](#)

Jirak P, Mirna M, Wernly B, Paar V, Thieme M, Betge S, Franz M, Hoppe U, Lauten A, Kammler J, Schulze PC, Lichtenauer M, Kretzschmar D. *Minerva Med.* 2018 Apr 12

[Effect of simvastatin and ezetimibe on suPAR levels and outcomes.](#)

Hodges GW, Bang CN, Forman JL, Olsen MH, Boman K, Ray S, Kesäniemi YA, Eugen-Olsen J, Greve AM, Jeppesen JL, Wachtell K. *Atherosclerosis.* 2018 May

[Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis.](#)

Wu W, Cui Y, Hu J, Liao R, Li S, Mo L, Xu L, Chen Y, Lian Z, Tian X, Li Z, Li R, Zhang L, Liang H, Ma J, Lin T, Feng Z, Dong W, Ke G, Ge P, Ye Z, Wang W, Zhang B, Shi W, Liang X, Liu S. *Kidney Blood Press Res.* 2018

[Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation.](#)

Koh AS, Velmurugan B, Gao F, Tan RS, Wong JI, Teo LLY, Keng BMH, Chua SJM, Yuan JM, Koh WP, Cheung C. *BMC Geriatr.* 2017 Nov 28

[Sepsis biomarkers reprofiling to predict stroke-associated infections.](#)

Bustamante A, García-Berrocoso T, Penalba A, Giralt D, Simats A, Muchada M, Zapata E, Rubiera M, Montaner J. *J Neuroimmunol.* 2017 Nov 15

[Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction.](#)

Fujisaka T, Fujita SI, Maeda D, Shibata K, Takahashi H, Morita H, Takeda Y, Ito T, Sohmiya K, Hoshiga M, Ishizaka N. *Heart Vessels.* 2017 Nov

[Prognostic and diagnostic potential of suPAR levels in pleural effusion.](#)

Matzkies LM, Raggam RB, Flick H, Rabensteiner J, Feierl G, Hoenigl M, Prattes J. J Infect. 2017 Nov

[A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure.](#)

Lichtenauer M, Jirak P, Wernly B, Paar V, Rohm I, Jung C, Schernthaner C, Kraus J, Motloch LJ, Yilmaz A, Hoppe UC, Christian Schulze P, Kretzschmar D, Pistulli R. Eur J Intern Med. 2017 Oct

[Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation.](#)

Ichihara N, Miyamura M, Maeda D, Fujisaka T, Fujita SI, Morita H, Takeda Y, Ito T, Sohmiya K, Hoshiga M, Ishizaka N. J Arrhythm. 2017 Oct

[Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.](#)

Samman Tahhan A, Hayek SS, Sandesara P, Hajjari J, Hammadah M, O'Neal WT, Kelli HM, Alkhoder A, Ghasemzadeh N, Ko YA, Aida H, Gafeer MM, Abdelhadi N, Mohammed KH, Patel K, Arya S, Reiser J, Vaccarino V, Sperling L, Quyyumi A. Atherosclerosis. 2017 Sep

[Peripheral arterial disease outcomes and association with suPAR: A bridge to myeloid precursors or mast cells or both?](#)

Hoebaus C, Yussuf SM, Valent P, Schernthaner GH. Atherosclerosis. 2017 Sep

[Multibiomarker analysis in patients with acute myocardial infarction.](#)

Schernthaner C, Lichtenauer M, Wernly B, Paar V, Pistulli R, Rohm I, Jung C, Figulla HR, Yilmaz A, Cadamuro J, Haschke-Becher E, Pernow J, Schulze PC, Hoppe UC, Kretzschmar D. Eur J Clin Invest. 2017 Sep

[Acute effects of moderate altitude on biomarkers of cardiovascular inflammation and endothelial function and their differential modulation by dual endothelin receptor blockade.](#)

Lichtenauer M, Goebel B, Paar V, Wernly B, Gecks T, Rohm I, Förster M, Betge S, Figulla HR, Hoppe UC, Kelm M, Franz M, Jung C. 2017

[Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients.](#)

Huang Y, Zhou H, Wu Y, Yang Y, Li W, Lu J, Hu Y. 2017

[Inflammatory markers associated with abdominal aortic aneurysm.](#)

Lindberg S, Zarrouk M, Holst J, Gottsäter A. 2016 Sep 1

[Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA.](#)

Onatsu J, Taina M, Mustonen P, Hedman M, Muuronen A, Arponen O, Korhonen M, Jäkälä P, Vanninen R, Pulkki K. In Vivo. 2017 May-Jun;31(3):381-386.

[Prognostic Outcomes in Patients With Heart Failure: A New SuPAR Biomarker for Risk Prediction?](#)

Pemberton C. JACC Heart Fail. 2017 Apr;5(4):278-279.

[Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.](#)

Koller L, Stojkovic S, Richter B, Sulzgruber P, Potolidis C, Liebhart F, Mörtl D, Berger R, Goliash G, Wojta J, Hülsmann M, Niessner A. JACC Heart Fail. 2017 Apr;5(4):268-277.

[Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death.](#)

Ghasemzedah N, Hayek SS, Ko YA, Eapen DJ, Patel RS, Manocha P, Al Kassem H, Khayata M, Veledar E, Kremastinos D, Thorball CW, Pielak T, Sikora S, Zafari AM, Lerakis S, Sperling L, Vaccarino V, Epstein SE, Quyyumi AA. *Circ Cardiovasc Qual Outcomes*. 2017 Mar;10(3).

[Serum Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated with Low Left Ventricular Ejection Fraction and Elevated Plasma Brain-Type Natriuretic Peptide Level.](#)

Fujita SI, Tanaka S, Maeda D, Morita H, Fujisaka T, Takeda Y, Ito T, Ishizaka N. *PLoS One*. 2017 Jan 30;12(1):e0170546.

[Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.](#)

Fagerberg B, Borné Y, Barregard L, Sallsten G, Forsgard N, Hedblad B, Persson M, Engström G. *Environ Res*. 2017 Jan;152:185-191.

[SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis.](#)

Hodges GW, Bang CN, Eugen-Olsen J, Olsen MH, Boman K, Ray S, Gohlke-Bärwolf C, Kesäniemi YA, Jeppesen JL, Wachtell K. *Can J Cardiol*. 2016 May 3. - **suPARnostic®**

[Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions.](#)

Ozsu S, Oztuna F, Mentese A, Abul Y, Ozlu T. *Clin Respir J*. 2016 Jan;10(1):61-6. - **suPARnostic®**

[Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness.](#)

Cyrille NB, Villablanca PA, Ramakrishna H. *Ann Card Anaesth*. 2016 Apr-Jun;19(2):214-6. - **suPARnostic®**

[suPAR: A New Biomarker for Cardiovascular Disease?](#)

Hodges GW, Bang CN, Wachtell K, Eugen-Olsen J, Jeppesen JL. *Can J Cardiol*. 2015 Oct;31(10):1293-302. Review.

[Soluble urokinase plasminogen activator receptor \(suPAR\) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.](#)

Rasmussen L, Knudsen A, Katzenstein TL, Gerstoft J, Obel N, Jørgensen NR, Kronborg G, Benfield T, Kjaer A, Eugen-Olsen J, Lebech AM. *HIV Med*. 2015 Sep 14. doi: 10.1111/hiv.12315. – **suPARnostic®**

[Three-year changes of prothrombotic factors in a cohort of South Africans with a high clinical suspicion of obstructive sleep apnea.](#)

von Känel R, Malan NT, Hamer M, Lambert GW, Schlaich M, Reimann M, Malan L. *Thromb Haemost*. 2015 Sep 3;115(1). – **suPARnostic®**

[suPAR: A Cardiac Biomarker With a Future?](#)

Arbel Y, Strauss BH. *Can J Cardiol*. 2015 Oct;31(10):1223-4. doi: 10.1016/j.cjca.2015.08.011. – **suPARnostic®**

[Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.](#)

Engström G, Zöller B, Svensson PJ, Melander O, Persson M. *Thromb Haemost*. 2015 Oct 15;115(3). – **suPARnostic®**

[PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis.](#)

Unsel M, Chilla A, Pausz C, Mawas R, Breuss J, Zielinski C, Schabbauer G, Prager GW. Thromb Haemost. 2015 Apr 30;114(2).

[Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis.](#)

Legány N, Toldi G, Distler JH, Beyer C, Szalay B, Kovács L, Vásárhelyi B, Balog A. Clin Chem Lab Med. 2015 Apr 18. – **suPARnostic®**

[Role of formic receptors in soluble urokinase receptor-induced human vascular smooth muscle migration.](#)

Duru EA, Fu Y, Davies MG. J Surg Res. 2015 May 15;195(2):396-405.

[The Inflammatory Marker suPAR After Cardiac Arrest.](#)

Rundgren M, Lyngbaek S, Fisker H, Friberg H. Ther Hypothermia Temp Manag. 2015 Jun;5(2):89-94. – **suPARnostic®**

[Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.](#)

Mekonnen G, Corban MT, Hung OY, Eshtehardi P, Eapen DJ, Al-Kassem H, Rasoul-Arzrumly E, Gogas BD, McDaniel MC, Pielak T, Thorball CW, Sperling L, Quyyumi AA, Samady H. Atherosclerosis. 2015 Mar;239(1):55-60. – **suPARnostic®**

[Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.](#)

Eapen DJ, Manocha P, Ghasemzedah N, Patel RS, Al Kassem H, Hammadah M, Veledar E, Le NA, Pielak T, Thorball CW, Velegraki A, Kremastinos DT, Lerakis S, Sperling L, Quyyumi AA. J Am Heart Assoc. 2014 Oct 23;3(5):e001118. – **suPARnostic®**

[Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use.](#)

Gozdzik W, Adamik B, Gozdzik A, Rachwalik M, Kustrzycki W, Kübler A. PLoS One. 2014 Jun 9;9(6):e98923. – **suPARnostic®**

[Relevance of novel inflammatory markers in stroke-induced immunosuppression.](#)

Folyovich A, Biró E, Orbán C, Bajnok A, Varga V, Béres-Molnár AK, Vásárhelyi B, Toldi G. BMC Neurol. 2014 Mar 6;14(1):41. – **suPARnostic®**

[Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.](#)

Borné Y, Persson M, Melander O, Smith JG, Engström G. Eur J Heart Fail. 2014 Jan. – **suPARnostic®**

[Soluble Urokinase Plasminogen Activator Receptor: A Risk Factor for Carotid Plaque, Stroke, and Coronary Artery Disease.](#)

Persson M, Ostling G, Smith G, Hamrefors V, Melander O, Hedblad B, Engström G. Stroke. 2013 Nov 19. – **suPARnostic®**

[Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.](#)

Asciutto G, Edsfeldt A, Dias NV, Nilsson J, Prehn C, Adamski J, Gonçalves I. Cardiovasc Pathol. 2013 Dec;22(6):438-43.

[Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.](#)

Lyngbæk S, Marott JL, Møller DV, Christiansen M, Iversen KK, Clemmensen PM, Eugen-Olsen J, Jeppesen JL, Hansen PR.

Am J Cardiol. 2012 Sep. 15;110(12):1756-63. – **suPARnostic®**

[Soluble urokinase plasminogen activator receptor in patients with abdominal aortic aneurysm.](#)

Lindqvist M, Wallinder J, Henriksson AE. Thromb Res. 2012 May 25.

[Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study.](#)

Schutte AE, Myburgh A, Olsen MH, Eugen-Olsen J, Schutte R.

Thromb Res. 2011 Aug;130(2):273-7- **suPARnostic®**

[Increased soluble urokinase plasminogen activator receptor \(suPAR\) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria \(PNH\) patients.](#)

Sloand EM, Pfannes L, Scheinberg P, More K, Wu CO, Horne M, Young NS.

Exp Hematol. 2008 Dec;36(12):1616-24.

7. Diabetes

[Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.](#)

Hayek SS, Divers J, Raad M, Xu J, Bowden DW, Tracy M, Reiser J, Freedman BI. J Am Heart Assoc. 2018 May 1

[Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.](#)

von Scholten BJ, Persson F, Rosenlund S, Eugen-Olsen J, Pielak T, Faber J, Hansen TW, Rossing P. Diabetes Obes Metab. 2017 Jan 20

[Soluble urokinase receptor \(suPAR\) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.](#)

Guthoff M, Wagner R, Randrianarisoa E, Hatzigelaki E, Peter A, Häring HU, Fritsche A, Heyne N. Sci Rep. 2017 Jan 16;7:40627.

[Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor \(suPAR\) in patients with type 2 diabetes.](#)

Persson F, Theilade S, Eugen-Olsen J, Rossing P, Parving HH. J Diabetes Complications. 2016 Nov

[Plasma soluble urokinase plasminogen activator receptor \(suPAR\) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease.](#)

Theilade S, Rossing P, Eugen-Olsen J, Jensen JS, Jensen MT. Eur J Endocrinol. **2016** Mar 7. - **suPARnostic®**

[Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.](#)

Theilade S, Lyngbaek S, Hansen TW, Eugen-Olsen J, Fenger M, Rossing P, Jeppesen JL.
J Intern Med. 2014 Mar;277(3):362-71. - **suPARnostic**[®]

[The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor \(suPAR\) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status.](#)

Heraclides A, Jensen TM, Rasmussen SS, Eugen-Olsen J, Haugaard SB, Borch-Johnsen K, Sandbæk A, Lauritzen T, Witte DR.
Diabetologia. 2013 Jul;56(7):1542-6. - **suPARnostic**[®]

8. Exercise and Physical Conditions

[Effect of a physical activity intervention on suPAR levels: A randomized controlled trial.](#)

Rohde C, Polcwiartek C, Andersen E, Vang T, Nielsen J. J Sci Med Sport. 2017 Jul 4

[Inflammation and post-operative recovery in patients undergoing total knee arthroplasty-secondary analysis of a randomized controlled trial.](#)

Langkilde A, Jakobsen TL, Bandholm TQ, Eugen-Olsen J, Blauenfeldt T, Petersen J, Andersen O.
Osteoarthritis Cartilage. 2017 Mar 16.

[Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema.](#)

Hilty MP, Zügel S, Schoeb M, Auinger K, Dehnert C, Maggiorini M. Mediators Inflamm. 2016;2016:1942460.
- **suPARnostic**[®]

[Acute Changes in Inflammatory Biomarker Levels in Recreational Runners Participating in a Marathon or Half-Marathon.](#)

Niemelä M, Kangastupa P, Niemelä O, Bloigu R, Juvonen T. Sports Med Open. 2016 Dec;2(1):21 -
suPARnostic[®]

[Association among Fibrinolytic Proteins, Metabolic Syndrome Components, Insulin Secretion, and Resistance in Schoolchildren.](#)

Chen JS, Wu CZ, Chu NF, Chang LC, Pei D, Lin YF.
Int J Endocrinol. 2015:170987.

[Life-long endurance exercise in humans: Circulating levels of inflammatory markers and leg muscle size.](#)

Mikkelsen UR, Couppe C, Karlsen A, Grosset JF, Schjerling P, Mackey A, Klausen HH, Magnusson SP, Kjær M.
Mech Ageing Dev. 2013 Nov 25. - **suPARnostic**[®]

9. Gastric Conditions

[A Preliminary Study of the Value of Plasma microRNA-193b and Soluble Urokinase-Type Plasminogen Activator Receptor in Identifying Patients with Early-Stage Colorectal Cancer and.](#)

Liu KL, Luo JL, Wu J, Wang YD, Fan HJ. Clin Lab. 2017 Nov 1

[Can serum soluble urokinase plasminogen activator receptor be an effective marker in the diagnosis of appendicitis and differentiation of complicated cases?](#)

Akın M, Erginel B, Sever N, Özel K, Bayraktar B, Yıldız A, Karadağ ÇA, Tokel M, Dokucu AI. Ulus Travma Acil Cerrahi Derg. 2018 Mar

[Serum levels of soluble urokinase plasminogen activator receptor \(suPAR\) predict outcome after resection of colorectal liver metastases.](#)

Loosen SH, Tacke F, Binnebosel M, Leyh C, Vucur M, Heitkamp F, Schoening W, Ulmer TF, Alizai PH, Trautwein C, Koch A, Longerich T, Roderburg C, Neumann UP, Luedde T. Oncotarget. 2018 Jun 5

[Soluble urokinase-type plasminogen activator receptor as a putative marker of male accessory gland inflammation.](#)

Autilio C, Morelli R, Milardi D, Grande G, Marana R, Pontecorvi A, Zuppi C, Baroni S. Andrology. 2015 Sep 18. doi: 10.1111/andr.12084

[Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer.](#)

Fidan E, Mentese A, Ozdemir F, Deger O, Kavgaci H, Caner Karahan S, Aydin F. Med Oncol. 2013 Jun;30(2):540.

10. General Population Studies

[Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity.](#)

Can U, Buyukinan M, Yerlikaya FH. Indian J Med Res. 2017 Mar

[Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood.](#)

Rasmussen LJH, Moffitt TE, Eugen-Olsen J, Belsky DW, Danese A, Harrington H, Houts RM, Poulton R, Sugden K, Williams B, Caspi A. J Child Psychol Psychiatry. 2018 May 9

[Impact of lifestyle intervention for obese women during pregnancy on maternal metabolic and inflammatory markers.](#)

Renault KM, Carlsen EM, Hædersdal S, Nilas L, Secher NJ, Eugen-Olsen J, Cortes D, Olsen SF, Halldorsson TI, Nørgaard K. Int J Obes (Lond). 2017 Apr;41(4):598-605.

[Usefulness of soluble urokinase plasminogen activator receptor \(suPAR\) as an inflammatory biomarker in obese children.](#)

Kosecik M, Dervisoglu P, Koroglu M, Isguven P, Elmas B, Demiray T, Altindis M. Int J Cardiol. 2017 Feb 1;228:158-161.

[Diagnostic Value of Upar, IL-33, and ST2 Levels in Childhood Sepsis.](#)

Çekmez F, Fidanci MK, Ayar G, Saldır M, Karaoglu A, Gündüz RC, Tunc T, Kalkan G. Clin Lab. 2016;62(5):751-5.

[Prognostic significance of APACHE II score and plasma suPAR in Chinese patients with sepsis: a prospective observational study.](#)

Liu X, Shen Y, Li Z, Fei A, Wang H, Ge Q, Pan S. BMC Anesthesiol. 2016 Jul 29;16(1):46

[Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.](#)

Engström G, Zöller B, Svensson PJ, Melander O, Persson M. *Thromb Haemost.* **2016** Feb 29;115(3):657-62. - [suPARnostic®](#)

[Plasma suPAR is lowered by smoking cessation: a randomized controlled study.](#)

Eugen-Olsen J, Ladelund S, Sørensen LT. *Eur J Clin Invest.* **2016** Apr;46(4):305-11. - [suPARnostic®](#)

[1C.01: SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A PROGNOSTIC MARKER OF ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN A BLACK POPULATION.](#)

Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Pretorius R, Schutte AE. *J Hypertens.* **2015** Jun;33 Suppl 1:e9. - [suPARnostic®](#)

[9A.06: IMPACT OF METABOLIC, HEMODYNAMIC AND INFLAMMATORY FACTORS ON TARGET ORGAN DAMAGE IN HEALTHY SUBJECTS.](#)

Blicher M, Kruger R, Olesen T, Greve S, Hansen T, Olsen MH. *J Hypertens.* **2015** Jun;33 Suppl 1:e118. - [suPARnostic®](#)

[Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years.](#)

Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Schutte AE. *Hypertens Res.* 2015 Mar 5. doi: 10.1038/hr.2015.22. - [suPARnostic®](#)

[Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.](#)

Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Pretorius R, Schutte AE. *Int J Cardiol.* 2015 Apr 1;184:631-6. - [suPARnostic®](#)

[Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.](#)

Haupt TH, Kallemsen T, Ladelund S, Rasmussen LJ, Thorball CW, Andersen O, Pisinger C, Eugen-Olsen J. *Biomark Insights.* 2014 Dec 16;9:91-100. - [suPARnostic®](#)

[Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.](#)

Sørensen MH, Gerke O, Eugen-Olsen J, Munkholm H, Lambrechtsen J, Sand NP, Mickley H, Rasmussen LM, Olsen MH, Diederichsen A. *Atherosclerosis.* 2014 Sep 2;237(1):60-66- [suPARnostic®](#)

[Associations of suPAR with lifestyle and cardiometabolic risk factors.](#)

Botha S, Fourie CM, Schutte R, Kruger A, Schutte AE. *Eur J Clin Invest.* 2014 Jul;44(7):619-26. - [suPARnostic®](#)

[The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor \(suPAR\) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status.](#)

Heraclides A, Jensen TM, Rasmussen SS, Eugen-Olsen J, Haugaard SB, Borch-Johnsen K, Sandbæk A, Lauritzen T, Witte DR. *Diabetologia.* 2013 Jul;56(7):1542-6.

[Soluble urokinase plasminogen activator receptor, C-reactive protein and triglyceride are associated with heart rate variability in non-diabetic Danes.](#)

Intzilakis T, Hartmann G, Mouridsen MR, Eugen-Olsen J, Kumarathurai P, Madsbad S, Almdal TP, Haugaard SB, Sajadieh A. Eur J Clin Invest. 2013 May;43(5):457-68. – **suPARnostic®**

[NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC study.](#)

Kruger R, Schutte R, Huisman HW, Hindersson P, Olsen MH, Eugen-Olsen J, Schutte AE. PLoS One. 2013;8(3):e58506. – **suPARnostic®**

[Soluble Urokinase Plasminogen Activator Receptor is Associated With Inflammation in the Vulnerable Human Atherosclerotic Plaque.](#)

Edsfeldt A, Nitulescu M, Grufman H, Grönberg C, Persson A, Nilsson M, Persson M, Björkbacka H, Gonçalves I. Stroke. 2012 Dec;43(12):3305-12. – **suPARnostic®**

[Cardiovascular risk prediction in the general population with use of **suPAR**, CRP, and Framingham Risk Score.](#)

Lyngbæk S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, Linneberg A, Haugaard SB, Eugen-Olsen J, Hansen PR, Jeppesen J. Int J Cardiol. 2012 Aug 18. – **suPARnostic®**

[CRP and **suPAR** are differently related to anthropometry and subclinical organ damage.](#)

Lyngbæk S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, Linneberg A, Madsbad S, Haugaard SB, Eugen-Olsen J, Jeppesen J. Int J Cardiol. 2012 Mar 27. – **suPARnostic®**

[The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men.](#)

Haugaard SB, Andersen O, Hansen TW, Eugen-Olsen J, Linneberg A, Madsbad S, Olsen MH, Jørgensen T, Borch-Johnsen K, Jeppesen J. Diabet Med. 2012 Apr;29(4):479-487. - **suPARnostic®**

[Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.](#)

Persson M, Engström G, Björkbacka H, Hedblad B. Atherosclerosis. 2012 Feb;220(2):502-5. - **suPARnostic®**

[Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Organ Damage And Cardiovascular Events](#)

T. Sehestedt, S. Lyngbæk, J. Eugen-Olsen, J. Jeppesen, O. Andersen, T.W. Hansen, A. Linneberg, T. Jørgensen, S.B. Haugaard and M.H. Olsen
Science Direct. 2011 May;216(1):237-43. – **suPARnostic®**

[Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.](#)

Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB. J Intern Med. 2010 Sep;268(3):296-308. – **suPARnostic®**

11. Hepatic Conditions

[Plasma Level of Soluble Urokinase-type Plasminogen Activator Receptor Predicts the Severity of Acute Alcohol Pancreatitis.](#)

Nikkola A, Aittoniemi J, Huttunen R, Rajala L, Nordback I, Sand J, Laukkarinen J. *Pancreas*. 2017 Jan;46(1):77-82.

[Soluble urokinase-type plasminogen activator receptor \(suPAR\) in patients with acute pancreatitis \(AP\) - Progress in prediction of AP severity.](#)

Lipinski M, Rydzewska-Rosolowska A, Rydzewski A, Cicha M, Rydzewska G. *Pancreatology*. 2017 Jan - Feb;17(1):24-29.

[Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma.](#)

Chounta A, Ellinas C, Tzanetakou V, Pliarhopoulou F, Mplani V, Oikonomou A, Leventogiannis K, Giamarellos-Bourboulis EJ. *Liver Int*. 2015 Feb;35(2):601-7. doi: – **suPARnostic®**.

[Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.](#)

Sjöwall C, Martinsson K, Cardell K, Ekstedt M, Kechagias S. *Transl Res*. 2014 Oct 5. pii: S1931-5244(14)00334-X. – **suPARnostic®**

[Serum soluble urokinase plasminogen activator receptor in alcoholics: relation to liver disease severity, fibrogenesis and alcohol use.](#)

Tuomi H, Kultti J, Danielsson J, Kangastupa P, Akerman K, Niemelä O. *J Gastroenterol Hepatol*. 2014 Jun 9. – **suPARnostic®**

[Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor \(suPAR\) in acute liver failure.](#)

Koch A, Zimmermann HW, Gassler N, Jochum C, Weiskirchen R, Bruensing J, Buendgens L, Dückers H, Bruns T, Gerken G, Neumann UP, Adams DH, Trautwein C, Canbay A, Tacke F. *Liver Int*. 2014 Oct;34(9):1330-9. – **suPARnostic®**

[CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.](#)

Cara-Fuentes G, Wei C, Segarra A, Ishimoto T, Rivard C, Johnson RJ, Reiser J, Garin EH. *Pediatr Nephrol*. 2013 Nov 22.

[Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis.](#)

Beaudreuil S, Zhang X, Kriaa F, Dantal J, Francois H, Vazquez A, Charpentier B, Lorenzo HK, Durrbach A. *Nephrol Dial Transplant*. 2013 Nov 13.

[CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutation.](#)

Cara-Fuentes G, Araya C, Wei C, Rivard C, Ishimoto T, Reiser J, Johnson RJ, Garin EH. *Nefrologia*. 2013;33(5):727-31.

[Cardiac and proinflammatory markers predict prognosis in cirrhosis.](#)

Wiese S, Mortensen C, Gøtze JP, Christensen E, Andersen O, Bendtsen F, Møller S.
Liver Int. 2013 Dec 7.– **suPARnostic®**

[No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.](#)

Mortensen C, Karlsen S, Grønbaek H, Nielsen DT, Frevert S, Clemmesen JO, Møller S, Jensen JS, Bendtsen F.
Liver Int. 2013 May 9. Oct;33(9):1309-15. – **suPARnostic®**

[Soluble urokinase plasminogen activator receptor \(suPAR\) is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.](#)

Zimmermann HW, Reuken PA, Koch A, Bartneck M, Adams DH, Trautwein C, Stallmach A, Tacke F, Bruns T.
J Intern Med. 2013 Feb 21. Mar;32(3):500-9. – **suPARnostic®**

[Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.](#)

Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F.
Liver Int. 2011 Mar;32(3):500-9.- **suPARnostic®**

[Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection.](#)

Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE.
J Clin Gastroenterol. 2011 Sep 19. Apr;46(4):334-8. - **suPARnostic®**

[Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1.](#)

Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, Weis N.
Eur J Clin Microbiol Infect Dis. 2011 Jan 13. doi: 10.1007/s10096-010-1149-y – **suPARnostic®**

12. Infectious Diseases and Inflammation

[Prognostic power of biomarkers for short-term mortality in the elderly patients seen in Emergency Departments due to infections.](#)

Julián-Jiménez A, Yañez MC, González-Del Castillo J, Salido-Mota M, Mora-Ordoñez B, Arranz-Nieto MJ, Chanovas-Borras MR, Llopis-Roca F, Mòdol-Deltell JM, Muñoz G; en representación del grupo INFURG-SEMES. Enferm Infecc Microbiol Clin. 2017 Dec 27

[Presepsin: A potential biomarker of PJI? A comparative analysis with known and new infection biomarkers.](#)

Marazzi MG, Randelli F, Brioschi M, Drago L, Romanò CL, Banfi G, Massaccesi L, Crapanzano C, Morelli F, Corsi Romanelli MM, Galliera E. Int J Immunopathol Pharmacol. 2018 Jan-Dec

[Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection.](#)

Kirkegaard-Klitbo DM, Langkilde A, Mejer N, Andersen O, Eugen-Olsen J, Benfield T. J Infect Dis. 2017 Oct 17 [Epub]

[How biomarkers reflect the prognosis and treatment of necrotising soft tissue infections and the effects of hyperbaric oxygen therapy: the protocol of the prospective cohort PROTREAT study conducted at a tertiary hospital in Copenhagen, Denmark.](#)

Polzik P, Johansson PI, Hyldegaard O. *BMJ Open*. 2017 Oct 5

[High pneumococcal DNA load, procalcitonin and suPAR levels correlate to severe disease development in patients with pneumococcal pneumonia.](#)

Loonen AJM, Kesarsing C, Kusters R, Hilbink M, Wever PC, van den Brule AJC. *Eur J Clin Microbiol Infect Dis*. 2017 Sep

[The intriguing role of soluble urokinase receptor in inflammatory diseases.](#)

Desmedt S, Desmedt V, Delanghe JR, Speeckaert R, Speeckaert MM. *Crit Rev Clin Lab Sci*. 2017 Mar;54(2):117-133.

[Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR.](#)

Rudolf F, Wagner AJ, Back FM, Gomes VF, Aaby P, Østergaard L, Eugen-Olsen J, Wejse C. *Int J Tuberc Lung Dis*. 2017 Jan 1;21(1):67-72.

[Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication.](#)

Tognoli E, Luigi Giuseppe Leoni M, Morelli D, Sottotetti E, Martinetti A, Signoroni S, Galeone C, Gallino G. *Wound Repair Regen*. 2016 Nov;24(6):1036-1040.

[Plasma levels of eight different mediators and their potential as biomarkers of various clinical malaria conditions in African children.](#)

Tahar R, Albergaria C, Zeghidour N, Ngane VF, Basco LK, Roussilhon C. *Malar J*. 2016 Jun 29;15:337

[Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study.](#)

Lindboe JB, Langkilde A, Eugen-Olsen J, Hansen BR, Haupt TH, Petersen J, Andersen O. *Infect Dis (Lond)*. 2016 Nov-Dec;48(11-12):829-37 - **suPARnostic®**

[Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B.](#)

Sevgi DY, Bayraktar B, Gündüz A, Özgüven BY, Togay A, Bulut E, Uzun N, Dökmetaş İ. *Wien Klin Wochenschr*. 2016 Jan;128(1-2):28-33. - **suPARnostic®**

[Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial.](#)

Kasang C, Kalluvya S, Majinge C, Kongola G, Mlewa M, Massawe I, Kabyemera R, Magambo K, Ulmer A, Klinker H, Gschmack E, Horn A, Koutsilieri E, Preiser W, Hofmann D, Hain J, Müller A, Dölken L, Weissbrich B, Rethwilm A, Stich A, Scheller C. *PLoS One*. 2016 Jan 26;11(1):e0146678. - **suPARnostic®**

[The diagnostic value of soluble urokinase plasminogen activator receptor compared with C-reactive protein and procalcitonin in children with febrile neutropenia.](#)

Sirinoglu M, Soysal A, Karaaslan A, Kadayıfci EK, Cinel I, Koç A, Tokuç G, Yaman A, Haklar G, Şirikçi Ö, Turan S, Gelmez GA, Söyletir G, Bakır M. *Pediatr Hematol Oncol*. 2016 Apr 8:1-9.- **suPARnostic®**

[Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls.](#)

Langkilde A, Petersen J, Henriksen JH, Jensen FK, Gerstoft J, Eugen-Olsen J, Andersen O. Immun Ageing. **2015** Aug 4;12:9. - [suPARnostic®](#)

[Serum soluble urokinase-type plasminogen activator receptor and interferon- \$\gamma\$ -induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B.](#)

Sevgi DY, Bayraktar B, Gündüz A, Özgüven BY, Togay A, Bulut E, Uzun N, Dökmetaş İ. Wien Klin Wochenschr. **2015** Nov 6.

[Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children.](#)

Wrotek A, Jackowska T, Pawlik K. Adv Exp Med Biol. 2015;835:1-7. - [suPARnostic®](#)

[The role of the soluble urokinase plasminogen activator \(suPAR\) in children with pneumonia.](#)

Wrotek A, Jackowska T. Respir Physiol Neurobiol. 2015 Apr;209:120-3. Review.

[Soluble urokinase-type plasminogen activator receptor \(suPAR\) as new biomarker of the prosthetic joint infection: Correlation with inflammatory cytokines.](#)

Galliera E, Drago L, Marazzi MG, Romanò C, Vassena C, Corsi Romanelli MM. Clin Chim Acta. 2015 Feb 20;441:23-8. - [suPARnostic®](#)

[Host Response Biomarker in Sepsis: suPAR Detection.](#)

Giamarellos-Bourboulis EJ, Georgitsi M. Methods Mol Biol. 2015;1237:241-6. - [suPARnostic®](#)

[Soluble Urokinase Plasminogen Activator Receptor: An Indicator of Pneumonia Severity in Children.](#)

Wrotek A, Jackowska T, Pawlik K. Adv Exp Med Biol. 2014 Oct 15. - [suPARnostic®](#)

[Clinical value of plasma soluble urokinase-type plasminogen activator receptor levels in term neonates with infection or sepsis: a prospective study.](#)

Sihanidou T, Margeli A, Tsirogianni C, Charoni S, Giannaki M, Vavourakis E, Charisiadou A, Papassotiriou I. Mediators Inflamm. 2014;2014:375702. - [suPARnostic®](#)

[Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.](#)

Outinen TK, Mäkelä S, Huttunen R, Mäenpää N, Libraty D, Vaheri A, Mustonen J, Aittoniemi J. J Intern Med. 2014 Oct;276(4):387-95. - [suPARnostic®](#)

[Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients.](#)

Donadello K, Scolletta S, Taccone FS, Covajes C, Santonocito C, Cortes DO, Grazulyte D, Gottin L, Vincent JL. J Crit Care. 2013 Feb;29(1):144-9. [suPARnostic®](#)

[Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute puumala hantavirus infection.](#)

Outinen TK, Tervo L, Mäkelä S, Huttunen R, Mäenpää N, Huhtala H, Vaheri A, Mustonen J, Aittoniemi J. PLoS One. 2013 Aug 21;8(8):e71335. - [suPARnostic®](#)

[HIV-1 Infected Lymphoid Organs Upregulate Expression and Release of the Cleaved Form of uPAR That Modulates Chemotaxis and Virus Expression.](#)

Nebuloni M, Zawada L, Ferri A, Tosoni A, Zerbi P, Resnati M, Poli G, Genovese L, Alfano M.
PLoS One. 2013 Jul 29;8(7):e70606.

[Role of biomarkers in the management of antibiotic therapy: an expert panel review: I - currently available biomarkers for clinical use in acute infections.](#)

Dupuy AM, Philippart F, Péan Y, Lasocki S, Charles PE, Chalumeau M, Claessens YE, Quenot JP, Guen CG, Ruiz S, Luyt CE, Roche N, Stahl JP, Bedos JP, Pugin J, Gauzit R, Misset B, Brun-Buisson C; Maurice Rapin Institute Biomarkers Group.
Ann Intensive Care. 2013 Jul 9;3(1):22.

[Soluble urokinase plasminogen activator receptor levels in tuberculosis patients at high risk for multidrug resistance.](#)

Mardining Raras TY, Astuti T, Noor Chozin I.
Tuberc Res Treat. 2012;2012:240132. - **suPARnostic®**

[Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study.](#)

Oliveira I, Andersen A, Furtado A, Medina C, da Silva D, da Silva ZJ, Aaby P, Laursen AL, Wejse C, Eugen-Olsen J; for the Bissau HIV cohort study group.
BMJ Open. 2012 Nov 14;2(6). – **suPARnostic®**

[Are Plasma Biomarkers of Immune Activation Predictive of HIV Progression: A Longitudinal Comparison and Analyses in HIV-1 and HIV-2 Infections?](#)

Nyamweya S, Townend J, Zaman A, Steele SJ, Jeffries D, Rowland-Jones S, Whittle H, Flanagan KL, Jaye A.
PLoS One. 2012;7(9):e44411.

[Utility of the Plasma Level of suPAR in Monitoring Risk of Mortality during TB Treatment.](#)

Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Haaland MB, Aaby P, Eugen-Olsen J.
PLoS One. 2012;7(8):e43933.– **suPARnostic®**

[HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients.](#)

Kasang C, Ulmer A, Donhauser N, Schmidt B, Stich A, Klinker, Kalluvya, Koutsilieri E, Rethwilm A, Scheller C.
BMC Infect Dis. 2012 Jan 20;12:14. - **suPARnostic®**

[Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome.](#)

Tzanakaki G, Paparoupa M, Kyprianou M, Barbouni A, Eugen-Olsen J, Kourea-Kremastinou J. Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):1157-62. - **suPARnostic®**

[Elevated soluble urokinase plasminogen activator receptor \(suPAR\) predicts mortality in Staphylococcus aureus bacteremia.](#)

Mölkänen T, Ruotsalainen E, Thorball CW, Järvinen A.
Eur J Clin Microbiol Infect Dis. 2011 Apr 12. PMID: 21479972 – **suPARnostic®**

[suPAR - a future risk marker.](#)

Eugen-Olsen J.
J Intern Med. 2011 Jul;270(1):29-31.Editorial– **suPARnostic®**

[Soluble Urokinase Plasminogen Activator Receptor \(suPAR\) is Associated with Metabolic Changes in HIV-1-Infected Africans: A Prospective Study.](#)

Fourie CM, Van Rooyen JM, Kruger A, Olsen MH, Eugen-Olsen J, Schutte R, Schutte AE. Inflammation. 2011 Feb;35(1):221-9.. – suPARnostic®

[Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study](#)

Huttunen R, Syrjänen R, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J. Journal of Internal Medicine. 2011 Feb. DOI: 10.1111/j.1365-2796.2011.02363.x – suPARnostic®

[Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study.](#)

Rabna P, Andersen A, Wejse C, Oliveira I, Francisco Gomes V, Bonde Haaland M, Aaby P, Eugen-Olsen J. Inflammation. 2010 Dec;33(6):374-80. – suPARnostic®

[High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test.](#)

Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Haaland MB, Aaby P, Eugen-Olsen J. Trop Med Int Health. 2009 Sep;14(9):986-94. – suPARnostic®

[Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response.](#)

Djoba Siawaya JF, Bapela NB, Ronacher K, Veenstra H, Kidd M, Gie R, Beyers N, van Helden P, Walzl G. J Infect. 2008 May;56(5):340-7.– suPARnostic®

[suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART.](#)

Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. J Infect. 2008 Jul;57(1):55-63.– suPARnostic®

[Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.](#)

Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. J Med Virol. 2008 Feb;80(2):209-16. – suPARnostic®

[The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms.](#)

Schneider UV, Nielsen RL, Pedersen C, Eugen-Olsen J. BMC Infect Dis. 2007 Nov 16;7:134. – suPARnostic®

[Plasma levels of soluble urokinase-type plasminogen activator receptor \(suPAR\) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa.](#)

Lawn SD, Myer L, Bangani N, Vogt M, Wood R. BMC Infect Dis. 2007 May 17;7:41. . – suPARnostic®

[Correlates for disease progression and prognosis during concurrent HIV/TB infection.](#)

Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G.

Int J Infect Dis. 2007 Jul;11(4):289-99. Review.

[Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study.](#)

Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, Larsen K.
Crit Care. 2007;11(2):R38. – **suPARnostic®**

[Elevated plasma urokinase receptor predicts low birth weight in maternal malaria.](#)

Ostrowski SR, Shulman CE, Peshu N, Staalsøe T, Høyer-Hansen G, Pedersen BK, Marsh K, Ullum H.
Parasite Immunol. 2007 Jan;29(1):37-46.

[Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.](#)

Ostrowski SR, Katzenstein TL, Pedersen M, Høyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H.
Scand J Immunol. 2006 Jun;63(6):478-86.

[Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.](#)

Ostrowski SR, Piironen T, Høyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H.
Scand J Immunol. 2005 Apr;61(4):347-56.

[High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients.](#)

Ostrowski SR, Piironen T, Høyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H.
J Acquir Immune Defic Syndr. 2005 May 1;39(1):23-31.

[Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells.](#)

Ostrowski SR, Plomgaard P, Fischer CP, Steensberg AS, Møller K, Høyer-Hansen G, Pedersen BK, Ullum H.
Scand J Immunol. 2005 Feb;61(2):197-206.

[Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.](#)

Sidenius N, Nebuloni M, Sala S, Zerbi P, Price RW, Gisslen M, Hagberg L, Vago L, Lazzarin A, Blasi F, Cinque P.
J Neuroimmunol. 2004 Dec;157(1-2):133-9.

[Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.](#)

Perch M, Kofoed P, Fischer TK, C6 F, Rombo L, Aaby P, Eugen-Olsen J.
Parasite Immunol. 2004 May;26(5):207-11. . – **suPARnostic®**

[Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients.](#)

Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H.
J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):337-42.

[Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome.](#)

Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J.
Scand J Infect Dis. 2004;36(1):14-9.

[The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau.](#)

Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I.
Int J Tuberc Lung Dis. 2002 Aug;6(8):686-92.

[Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.](#)

Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J.
Blood. 2000 Dec 15;96(13):4091-5.

13.Mental Diseases

[The relationship between levels of plasma-soluble urokinase plasminogen activator receptor \(suPAR\) and presence of migraine attack and aura.](#)

Yılmaz N, Yılmaz M, Sirin B, Yilmaztekin S, Kutlu G. J Recept Signal Transduct Res. 2017 Oct

[Effects of Acute Exercise on Circulating Soluble Form of the Urokinase Receptor in Patients With Major Depressive Disorder.](#)

Gustafsson A, Ventorp F, Wisén AG, Ohlsson L, Ljunggren L, Westrin Å.
Biomark Insights. 2017 Apr 12;12:1177271917704193.

[Serum soluble urokinase-type plasminogen activator receptor levels in male patients with acute exacerbation of schizophrenia.](#)

Genc A, Kalelioglu T, Karamustafalioglu N, Tasdemir A, Genc ES, Akkus M, Emul M.
Psychiatry Res. 2016 Feb 28;236:179-81.

[Increased Soluble Urokinase-Type Plasminogen Activator Receptor \(suPAR\) Levels in Plasma of Suicide Attempters.](#)

Ventorp F, Gustafsson A, Träskman-Bendz L, Westrin Å, Ljunggren L.
PLoS One. 2015 Oct 9;10(10):e0140052. . – suPARnostic®

[Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia.](#)

Nielsen J, Røge R, Pristed SG, Viuff AG, Ullum H, Thørner LW, Werge T, Vang T.
Schizophr Bull. 2015 May;41(3):764-71. . – suPARnostic®

14.Nephrology Conditions

[Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.](#)

Hayek SS, Ko YA, Awad M, Ahmed H, Gray B, Hosny KM, Aida H, Tracy MJ, Wei C, Sever S, Reiser J, Quyyumi AA. Kidney Int Rep. 2017 Feb 9

[Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients.](#)

Wlazeł RN, Szadkowska I, Bartnicki P, Rośniak-Bąk K, Rysz J. Int Urol Nephrol. 2018 Feb

[Evaluation of serum soluble urokinase plasminogen activator receptor as a marker for steroid-responsiveness in children with primary nephrotic syndrome.](#)

Mousa SO, Saleh SM, Aly HM, Amin MH. Saudi J Kidney Dis Transpl. 2018 Mar-Apr

[The clinical pattern of nephrotic syndrome in children has no effect on the concentration of soluble urokinase receptor \(suPAR\) in serum and urine.](#)

Ochocińska A, Jarmużek W, Janas R. Pol Merkur Lekarski. 2018 Apr 23

[What is the Role of Soluble Urokinase-Type Plasminogen Activator in Renal Disease?](#)

Saleem MA. Nephron. 2018 Jun 15 [epub]

[Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.](#)

Luo S, Coresh J, Tin A, Rebholz CM, Chen TK, Hayek SS, Tracy M, Lipkowitz MS, Appel LJ, Levey AS, Inker LA, Reiser J, Grams ME. Clin J Am Soc Nephrol. 2018 Jun 14 [epub]

[Molecular and Cellular Mechanisms for Proteinuria in Minimal Change Disease.](#)

Bertelli R, Bonanni A, Caridi G, Canepa A, Ghiggeri GM. Front Med (Lausanne). 2018 Jun 11

[Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.](#)

Schaefer F, Trachtman H, Wühl E, Kirchner M, Hayek SS, Anarat A, Duzova A, Mir S, Paripovic D, Yilmaz A, Lugani F, Arbeiter K, Litwin M, Oh J, Matteucci MC, Gellermann J, Wygoda S, Jankauskiene A, Klaus G, Dusek J, Testa S, Zurowska A, Caldas Afonso A, Tracy M, Wei C, Sever S, Smoyer W, Reiser J; ESCAPE Trial Consortium and the 4C Study Group. JAMA Pediatr. 2017 Nov 6

[Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.](#)

Kim EY, Roshanravan H, Dryer SE. Biochim Biophys Acta. 2017 Sep

[Experimental concerns regarding suPAR-related proteinuria.](#)

Mesnard L, Luque Y, Rondeau E. Nat Rev Nephrol. 2017 Sep

[Chronic kidney disease: Role of suPAR in APOL1-associated kidney disease.](#)

Carney EF. Nat Rev Nephrol. 2017 Sep

[A tripartite complex of suPAR, APOL1 risk variants and \$\alpha_5\beta_3\$ integrin on podocytes mediates chronic kidney disease.](#)

Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J. Nat Med. 2017 Aug

[suPAR and chronic kidney disease-a podocyte story.](#)

Zeier M, Reiser J. Pflugers Arch. 2017 Aug

[Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.](#)

Mossanen JC, Pracht J, Jansen TU, Buendgens L, Stoppe C, Goetzenich A, Struck J, Autschbach R, Marx G, Tacke F. *Int J Mol Sci.* 2017 Jul 31

[Extrarenal determinants of kidney filter function.](#)

Hahm E, Peev V, Reiser J. *Cell Tissue Res.* 2017 Ju

[Unwinding focal segmental glomerulosclerosis.](#)

Peev V, Hahm E, Reiser J. 2017 Apr 12

[Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.](#)

Dande RR, Peev V, Altintas MM, Reiser J. 2017

[Kidney disease in Puumala hantavirus infection.](#)

Mustonen J, Outinen T, Laine O, Pörsti I, Vaehri A, Mäkelä S. *Infect Dis (Lond).* 2017 May;49(5):321-332.

[Glomerular disease: A **suPAR** kidney connection found in the bone marrow.](#)

Gallon L, Quaggin SE. *Nat Rev Nephrol.* 2017 May;13(5):263-264.

[SCUBE1: a promising biomarker in renal cell cancer.](#)

Karagüzel E, Menteşe A, Kazaz İO, Demir S, Örem A, Okatan AE, Altay DU, Yaman SÖ. *Int Braz J Urol.* 2017 Apr 6;43.

[Soluble Urokinase-type Plasminogen Activator Receptor \(**suPAR**\) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.](#)

Schulz CA, Persson M, Christensson A, Hindy G, Almgren P, Nilsson PM, Melander O, Engström G, Orho-Melander M. *Kidney Int Rep.* 2017 Mar;2(2):239-247.

[Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7.](#)

Pofi R, Fiore D, De Gaetano R, Panio G, Gianfrilli D, Pozza C, Barbagallo F, Xiang YK, Giannakakis K, Morano S, Lenzi A, Naro F, Isidori AM, Venneri MA. *Sci Rep.* 2017 Mar 15;7:44584.

[Removal of focal segmental glomerulosclerosis \(FSGS\) factor **suPAR** using CytoSorb.](#)

Schenk H, Müller-Deile J, Schmitt R, Bräsen JH, Haller H, Schiffer M. *J Clin Apher.* 2017 Mar 29.

[Bone marrow-derived immature myeloid cells are a main source of circulating **suPAR** contributing to proteinuric kidney disease.](#)

Hahm E, Wei C, Fernandez I, Li J, Tardi NJ, Tracy M, Wadhwani S, Cao Y, Peev V, Zloza A, Lusciks J, Hayek SS, O'Connor C, Bitzer M, Gupta V, Sever S, Sykes DB, Scadden DT, Reiser J. *Nat Med.* 2017 Jan;23(1):100-106.

[Usefulness of sCD14-ST in the diagnosis of sepsis in patient with renal failure.](#)

Galeano D, Zanolli L, Fatuzzo P, Granata A. *G Ital Nefrol.* 2016 Mar-Apr;33(2).

[Circulating **suPAR** as a biomarker of disease severity in children with proteinuric glomerulonephritis.](#)

Soltysiak J, Zachwieja J, Benedyk A, Lewandowska-Stachowiak M, Nowicki M, Ostalska-Nowicka D. *Minerva Pediatr.* 2016 Apr 12.

[Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates.](#)

Königshausen E, Sellin L. Biomed Res Int. 2016;2016:3765608.

[Patients With Combined Membranous Nephropathy and Focal Segmental Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles With Primary Membranous Nephropathy: A Retrospective Observational Study.](#)

Gu QH, Cui Z, Huang J, Zhang YM, Qu Z, Wang F, Wang X, Wang SX, Liu G, Zhao MH. Medicine (Baltimore). 2016 May;95(21):e3786

[Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor \(suPAR\) in patients with type 2 diabetes.](#)

Persson F, Theilade S, Eugen-Olsen J, Rossing P, Parving HH. J Diabetes Complications. 2016 Nov - Dec;30(8):1440-1442 - suPARnostic®

[Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.](#)

Kronbichler A, Saleem MA, Meijers B, Shin JI. J Immunol Res. 2016;2016:2068691

[Sclerostin, TNF-alpha and Interleukin-18 Correlate and are Together with Klotho Related to Other Growth Factors and Cytokines in Haemodialysis Patients.](#)

Almroth G, Lönn J, Uhlén F, Brudin L, Andersson B, Hahn-Zoric M. Scand J Immunol. 2016 Jan;83(1):58-63. - suPARnostic®

[The glomerular permeability factors in idiopathic nephrotic syndrome.](#)

Davin JC. Pediatr Nephrol. 2016 Feb;31(2):207-15.

[Chronic kidney disease: suPAR in CKD.](#)

Allison SJ. Nat Rev Nephrol. 2016 Jan;12(1):3. - suPARnostic®

[Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.](#)

Chen JS, Chang LC, Wu CZ, Tseng TL, Lin JA, Lin YF, Cheng CW. J Biomed Sci. 2016 Feb 4;23(1):24.

[Soluble Urokinase Receptor and Chronic Kidney Disease.](#)

Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhvani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J.

N Engl J Med. 2015 Nov 12;373(20):1916-25. - suPARnostic®

[A suPAR Biomarker for Chronic Kidney Disease.](#)

Skorecki KL, Freedman BI.

N Engl J Med. 2015 Nov 12;373(20):1971-2. - suPARnostic®

[Circulating CD40 autoantibody and suPAR synergy drives glomerular injury. Wei C, Sigdel TK, Sarwal MM, Reiser J.](#)

Ann Transl Med. 2015 Nov;3(19):300.

[Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.](#)

Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, Savin VJ, Sharma M, Reiser J, Wei C, Somers M, Srivastava T, Gipson DS.
BMC Nephrol. **2015** Jul 22;16:111.

[Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.](#)

Zhao Y, Liu L, Huang J, Shi S, Lv J, Liu G, Zhao M, Zhang H.
PLoS One. **2015** Jul 13;10(7):e0132869.

[Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.](#)

Wu CZ, Chang LC, Lin YF, Hung YJ, Pei D, Chu NF, Chen JS.
Clin Biochem. **2015** Jul 8. pii: S0009-9120(15)00262-3.

[Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.](#)

Jin J, Li YW, He Q.
Transplant Proc. **2015** Jul-Aug;47(6):1760-5.

[Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte \$\beta\$ 3-integrin Activation.](#)

Staeck O, Slowinski T, Lieker I, Wu K, Rudolph B, Schmidt D, Brakemeier S, Neumayer HH, Wei C, Reiser J, Budde K, Halleck F, Khadzhyrov D.
Transplantation. **2015** Dec;99(12):2593-7.

[Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.](#)

Guo SM, Han M, Chen MX, Ning Y, Pei GC, Li YQ, Dai W, Ge SW, Deng YJ, Guo YY, Li XQ, Haller H, Xu G, Rong S. PLoS One. **2015** Sep 18;10(9):e0138718.

[Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.](#)

Alfano M, Cinque P, Giusti G, Proietti S, Nebuloni M, Danese S, D'Alessio S, Genua M, Portale F, Lo Porto M, Singhal PC, Rastaldi MP, Saleem MA, Mavilio D, Mikulak J. Sci Rep. **2015** Sep 18;5:13647.

[Sclerostin, TNF-alpha and interleukin-18 correlate and are together with Klotho related to other growth factors and cytokines in hemodialysis patients.](#)

Almroth G, Lönn J, Uhlin F, Brudin L, Andersson B, Hahn-Zoric M.
Scand J Immunol. **2015** Oct 8. doi: 10.1111/sji.12392.

[Chronic kidney disease: suPAR in CKD.](#)

Allison SJ.
Nat Rev Nephrol. **2015** Nov 23. – suPARnostic®

[A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues.](#)

Wada T, Nangaku M. Clin Kidney J. **2015** Dec;8(6):708-715. Review.

[Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.](#)

Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, Naesens M, Storr M, Kuypers D, Evenepoel P.

Kidney Int. 2014 Jun 4. doi: 10.1038/ki.2014.197.

[Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence.](#)

Mujtaba MA, Sharfuddin AA, Book BL, Goggins WC, Khalil AA, Mishler DP, Fridell JA, Yaqub MS, Taber TE.

Clin Transplant. 2015 May 12. doi: 10.1111/ctr.12562.

[The glomerular permeability factors in idiopathic nephrotic syndrome.](#)

Davin JC. Pediatr Nephrol. 2015 Apr 30.

[A case report of adrenocorticotrophic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring.](#)

Anwar S, Larson DS, Naimi N, Ashraf M, Culiberk N, Liapis H, Wei C, Reiser J, Brennan DC.

Front Med (Lausanne). 2015 Mar 20;2:13.

[Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.](#)

Musetti C, Quaglia M, Cena T, Chiochetti A, Monti S, Clemente N, Magnani C, Dianzani U, Stratta P.

J Nephrol. 2015 Jun;28(3):299-305.

[Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.](#)

Peng Z, Mao J, Chen X, Cai F, Gu W, Fu H, Shen H, Wang J, Jin X, Zhu X, Liu A, Shu Q, Du L.

Pediatr Nephrol. 2015 Feb;30(2):301-7.

[A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.](#)

Spinale JM, Mariani LH, Kapoor S, Zhang J, Weyant R, Song PX, Wong HN, Troost JP, Gadegbeku CA, Gipson DS, Kretzler M, Nihalani D, Holzman LB; Investigators of the Nephrotic Syndrome Study Network.

Kidney Int. 2015 Mar;87(3):564-74.

[Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future.](#)

Maas RJ, Deegens JK, Wetzels JF.

Nephrol Dial Transplant. 2014 Dec;29(12):2207-16.

[Biomarkers of Kidney Injury and Klotho in Patients with Atherosclerotic Renovascular Disease.](#)

Park MY, Herrmann SM, Saad A, Eirin A, Tang H, Lerman A, Textor SC, Lerman LO.

Clin J Am Soc Nephrol. 2014 Dec 26. pii: CJN.07290714.

[Clinical significance of serum and urinary soluble urokinase receptor \(suPAR\) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.](#)

Fujimoto K, Imura J, Atsumi H, Matsui Y, Adachi H, Okuyama H, Yamaya H, Yokoyama H.

Clin Exp Nephrol. 2014 Dec 13.

[Relationship between Serum Soluble Urokinase Plasminogen Activator Receptor Level and Steroid Responsiveness in FSGS.](#)

Li F, Zheng C, Zhong Y, Zeng C, Xu F, Yin R, Jiang Q, Zhou M, Liu Z.
Clin J Am Soc Nephrol. 2014 Oct 15. pii: CJN.02370314.

[Diabetes mellitus in the transplanted kidney.](#)

Peev V, Reiser J, Alachkar N.
Front Endocrinol (Lausanne). 2014 Aug 27;5:141. Review.

[Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.](#)

Musetti C, Quaglia M, Cena T, Chiocchetti A, Monti S, Clemente N, Magnani C, Dianzani U, Stratta P.
J Nephrol. 2014 Sep 4. Jun;28(3):299-305.

[Permeability factors in focal and segmental glomerulosclerosis.](#)

Reiser J, Nast CC, Alachkar N.
Adv Chronic Kidney Dis. 2014 Sep;21(5):417-21. Review.

[A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.](#)

Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, Burke GW, Bruneval P, Naesens M, Jackson A, Alachkar N, Canaud G, Legendre C, Anglicheau D, Reiser J, Sarwal MM.
Sci Transl Med. 2014 Oct 1;6(256):256ra136.

[Sphingomyelinase-Like Phosphodiesterase 3b Expression Levels Determine Podocyte Injury Phenotypes in Glomerular Disease.](#)

Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, Mitrofanova A, Leclercq F, Faul C, Li J, Kretzler M, Nelson RG, Lehto M, Forsblom C, Groop PH, Reiser J, Burke GW, Fornoni A, Merscher S.
J Am Soc Nephrol. 2014 Jun 12. pii: ASN.2013111213.

[suPAR and Team Nephrology.](#)

Trachtman H.
BMC Med. 2014 May 20;12(1):82.

[Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.](#)

Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Zhao MH.
BMC Med. 2014 May 20;12(1):81.

[Administration of Recombinant Soluble Urokinase Receptor Per Se Is Not Sufficient to Induce Podocyte Alterations and Proteinuria in Mice.](#)

Cathelin D, Placier S, Ploug M, Verpont MC, Vandermeersch S, Luque Y, Hertig A, Rondeau E, Mesnard L.
J Am Soc Nephrol. 2014 May 1.

[Correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malaria.](#)

Plewes K, Royackers AA, Hanson J, Hasan MM, Alam S, Ghose A, Maude RJ, Stassen PM, Charunwatthana P, Lee SJ, Turner GD, Dondorp AM, Schultz MJ.
Malar J. 2014 Mar 12;13(1):91. – **suPARnostic®**

[Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?](#)

Schlöndorff D. *Kidney Int.* 2014 Mar;85(3):499-501. doi: 10.1038/ki.2013.549.

[Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.](#)

Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, Dinda AK, Agarwal SK, Sopory S, Pandey RM, Hari P, Bagga A. *Kidney Int.* 2014 Mar;85(3):649-58.

[A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.](#)

Wada T, Nangaku M, Maruyama S, Imai E, Shoji K, Kato S, Endo T, Muso E, Kamata K, Yokoyama H, Fujimoto K, Obata Y, Nishino T, Kato H, Uchida S, Sasatomi Y, Saito T, Matsuo S. *Kidney Int.* 2014 Mar;85(3):641-8.

[The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.](#)

Meijers B, Maas RJ, Sprangers B, Claes K, Poesen R, Bammens B, Naesens M, Deegens JK, Dietrich R, Storr M, Wetzels JF, Evenepoel P, Kuypers D. *Kidney Int.* 2014 Mar;85(3):636-40.

[Recurrence of glomerulonephritis after renal transplantation.](#)

Sprangers B, Kuypers DR. *Transplant Rev (Orlando)*. 2013 Aug 14.

[Has the circulating permeability factor in primary FSGS been found?](#)

Ashley Jefferson J, Shankland SJ. *Kidney Int.* 2013 Aug;84(2):235-8.

[Circulating Permeability Factor suPAR: From Concept to Discovery to Clinic.](#)

Reiser J. *Trans Am Clin Climatol Assoc.* 2013;124:133-8.

[Podocyte Effacement Closely Links to suPAR Levels at Time of Posttransplantation Focal Segmental Glomerulosclerosis Occurrence and Improves With Therapy.](#)

Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM. *Transplantation.* 2013 Jul 9.

[Urine But Not Serum Soluble Urokinase Receptor \(suPAR\) May Identify Cases of Recurrent FSGS in Kidney Transplant Candidates.](#)

Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H. *Transplantation.* 2013 Jun 3.

[Serum Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Idiopathic FSGS in Children: A Single-Center Report.](#)

Bock ME, Price HE, Gallon L, Langman CB. *Clin J Am Soc Nephrol.* 2013 Apr 25.

[Serum suPAR in patients with FSGS: trash or treasure?](#)

Maas RJ, Deegens JK, Wetzels JF.
Pediatr Nephrol. 2013 Mar 21.

[Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.](#)

Morath C, Wei C, Macher-Goeppinger S, Schwenger V, Zeier M, Reiser J.
Am J Ther. 2013 Mar;20(2):226-9.

[Glomerular disease: 'suPAR'-exciting times for FSGS.](#)

Jefferson JA, Alpers CE.
Nat Rev Nephrol. 2013 Mar;9(3):127-8.

[Transmission of Glomerular Permeability Factor Soluble Urokinase Plasminogen Activator Receptor \(suPAR\) From a Mother to Child.](#)

Kemper MJ, Wei C, Reiser J.
Am J Kidney Dis. 2012 Nov 19. doi:pii: S0272-6386(12)01333-9

[Circulating suPAR in Two Cohorts of Primary FSGS.](#)

Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J; for the PodoNet and FSGS CT Study Consortia.
J Am Soc Nephrol. 2012 Dec;23(12):2051-2059.

[Soluble urokinase plasminogen activator receptor \(suPAR\) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission.](#)

Toldi G, Bekó G, Kádár G, Mácsai E, Kovács L, Vásárhelyi B, Balog A.
Clin Chem Lab Med. 2012 Jun 21;0(0):1-6. – suPARnostic®

[Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.](#)

Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, Schultz MJ.
Intensive Care Med. 2012 Jun 16. – suPARnostic®

[Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?](#)

Pawlak K, Ulazka B, Mysliwiec M, Pawlak D. Transl Res. 2012 May 8.

[Targeting signaling pathways in glomerular diseases.](#)

Henique C, Tharaux PL. Curr Opin Nephrol Hypertens. 2012 Jul;21(4):417-27.

[Soluble urokinase receptor and focal segmental glomerulosclerosis.](#)

Reiser J, Wei C, Tumlin J. Curr Opin Nephrol Hypertens. 2012 Jul;21(4):428-32.

[A suPAR circulating factor causes kidney disease](#)

Shankland SJ, Pollak MR
Nat Med. 2011 Aug 4;17(8):926-7.

[Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.](#)

Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J.

Nat Med. 2011 Jul 31;17(8):952-60.

[Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.](#)

Pawlak K, Buraczewska-Buczko A, Mysliwiec M, Pawlak D.

Am J Med Sci. 2010 Jan;339(1):5-9.

[Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.](#)

Pawlak K, Pawlak D, Mysliwiec M.

Thromb Res. 2007;119(4):475-80.

15. Pulmonary Conditions

[Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study.](#)

Luo Q, Ning P, Zheng Y, Shang Y, Zhou B, Gao Z. Crit Care. 2018 Jan 24

[Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.](#)

Godtfredsen NS, Jørgensen DV, Marsaa K, Ulrik CS, Andersen O, Eugen-Olsen J, Rasmussen LJH.

Respir Res. 2018 May 21

[Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.](#)

Kaminski TW, Pawlak K, Karbowska M, Mysliwiec M, Grzegorzewski W, Kuna J, Pawlak D. Int Urol Nephrol. 2017 Oct 22. [Epub]

[Nephrotic syndrome in infants and children: pathophysiology and management.](#)

Downie ML, Gallibois C, Parekh RS, Noone DG. Paediatr Int Child Health. 2017 Sep 15

[SuPAR and FSGS: is the jury still out?](#)

Gallon L, Quaggin SE. Nat Rev Nephrol. 2017 Sep

[Serum levels of soluble urokinase plasminogen activator receptor \(suPAR\) as a marker of tuberculosis treatment efficacy.](#)

Indumati V, Vijay V, Krishnaswamy D, Rajeshwari V, Ramesh A, Shantala D, Shilpa A. Indian J Tuberc. 2017 Jul

[Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.](#)

Wang H, Yang T, Li D, Wu Y, Zhang X, Pang C, Zhang J, Ying B, Wang T, Wen F.

Int J Chron Obstruct Pulmon Dis. 2016 Sep 26;11:2369-2376.

[Can soluble urokinase plasminogen activator \(suPAR\) be used as a biomarker for ventilator-associated pneumonia?](#)

Sunnetcioglu A, Sunnetcioglu M, Adiyaman F, Binici I.
Clin Respir J. 2015 Dec 19. – suPARnostic®

[Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children.](#)

Wrotek A, Jackowska T, Pawlik K.
Adv Exp Med Biol. 2015;835:1-7. – suPARnostic®

[Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.](#)

Gumus A, Altintas N, Cinarka H, Kirbas A, Haziroglu M, Karatas M, Sahin U.
Int J Chron Obstruct Pulmon Dis. 2015 Feb 13;10:357-65. – suPARnostic®

[The role of the soluble urokinase plasminogen activator \(suPAR\) in children with pneumonia.](#)

Wrotek A, Jackowska T.
Respir Physiol Neurobiol. 2015 Jan 17. Review. – suPARnostic®

[SuPAR in pleural fluid may function as a biological marker for infection in critically ill patients with pleural effusions.](#)

Bakker OG, Hemmes SN, Backes Y, Determann RM, Schultz MJ.
J Infect. 2014 Feb 15. pii: S0163-4453(14)00041-3. – suPARnostic®

[Predictive Value of Soluble Urokinase Plasminogen Activator Receptor, Soluble ST2 and IL-33 in Bronchopulmonary Dysplasia.](#)

Tunc T, Cekmez F, Yildirim S, Bulut O, Ince Z, Saldir M, Aydemir G, Yaman H, Coban A.
Pediatr Res. 2014 Mar 6. Jun;75(6):788-92.

[Soluble receptor for urokinase plasminogen activator in community-acquired pneumonia in children.](#)

Wrotek A, Pawlik K, Jackowska T.
Adv Exp Med Biol. 2013;788:329-34. – suPARnostic®

[Relationship of circulating soluble urokinase plasminogen activator receptor \(suPAR\) levels to disease control in asthma and asthmatic pregnancy.](#)

Ivancsó I, Toldi G, Bohács A, Eszes N, Müller V, Rigó J Jr, Vásárhelyi B, Losonczy G, Tamási L.
PLoS One. 2013;8(4):e60697.. – suPARnostic®

[SuPAR and PAI-1 in critically ill, mechanically ventilated patients.](#)

Jalkanen V, Yang R, Linko R, Huhtala H, Okkonen M, Varpula T, Pettilä V, Tenhunen J; The FINNALI Study Group.
Intensive Care Med. 2012 Oct 26. – suPARnostic®

[Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study.](#)

Backes Y, van der Sluijs KF, Tuip de Boer AM, Hofstra JJ, Vlaar AP, Determann RM, Knape P, Mackie DP, Schultz MJ.
Crit Care. 2011 Nov 16;15(6):R270 - suPARnostic®

[Preoperative concentrations of suPAR and MBL proteins are associated with the development of pneumonia after elective surgery for colorectal cancer.](#)

Svendsen MN, Ytting H, Brünner N, Nielsen HJ, Christensen IJ. Surg Infect (Larchmt). 2006 Oct;7(5):463-71.

16.Sepsis and SIRS conditions

[Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis.](#)

Zhao JJ, Lou XL, Chen HW, Zhu FT, Hou YQ. Cell Mol Biol Lett. 2018 May 9

[Novel biomarkers for sepsis: A narrative review.](#)

Larsen FF, Petersen JA. Eur J Intern Med. 2017 Nov

[High pneumococcal DNA load, procalcitonin and suPAR levels correlate to severe disease development in patients with pneumococcal pneumonia.](#)

Loonen AJ, Kesarsing C, Kusters R, Hilbink M, Wever PC, van den Brule AJ. Eur J Clin Microbiol Infect Dis. 2017 Mar 29. doi: 10.1007/s10096-017-2963-2

[Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.](#)

Xiao Y, Luo H, Zhou B, Dai X, Huang J, Duan L, You Y, Zhang W, Zhao H, Xie Y, Zhou Y, Ning W, Li T, Liu S, Zhu H, Xie X, Jiang Y, Wu S, He W, Li Y. Rheumatol Int. 2017 Apr;37(4):585-592.

[Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.](#)

Ni W, Han Y, Zhao J, Cui J, Wang K, Wang R, Liu Y. Sci Rep. 2016 Dec 19

[Role of suPAR and Lactic Acid in Diagnosing Sepsis and Predicting Mortality in Elderly Patients.](#)

Khater WS, Salah-Eldeen NN, Khater MS, Saleh AN. Eur J Microbiol Immunol (Bp). 2016 Jul 19;6(3):178-185

[The diagnostic value of soluble urokinase plasminogen activator receptor \(suPAR\) compared to C-reactive protein \(CRP\) and procalcitonin \(PCT\) in children with systemic inflammatory response syndrome \(SIRS\).](#)

Şirinoğlu M, Soysal A, Karaaslan A, Kepenekli Kadayıfci E, Yalındağ-Öztürk N, Cinel İ, Yaman A, Haklar G, Şirikci Ö, Turan S, Altınkanat Gelmez G, Söyletir G, Bakır M. J Infect Chemother. 2016 Oct 19 - suPARnostic®

[Thrombocytopenia in critically ill patients with severe sepsis/septic shock: Prognostic value and association with a distinct serum cytokine profile.](#)

Tsirigotis P, Chondropoulos S, Frantzeskaki F, Stamouli M, Gkirkas K, Bartzeliotou A, Papanikolaou N, Atta M, Papassotiriou I, Dimitriadis G, Dimopoulou I. J Crit Care. 2016 Apr;32:9-15. - suPARnostic®

[Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis.](#)

Zeng M, Chang M, Zheng H, Li B, Chen Y, He W, Huang C. Am J Emerg Med. 2016 Mar;34(3):375-80.

[Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.](#)

El-Mekkawy MS, Saleh NY, Sonbol AA. Indian J Pediatr. 2016 Mar 10. - suPARnostic®

[Thrombocytopenia in critically ill patients with severe sepsis/septic shock: Prognostic value and association with a distinct serum cytokine profile.](#)

Tsirigotis P, Chondropoulos S, Frantzeskaki F, Stamouli M, Gkirkas K, Bartzeliotou A, Papanikolaou N, Atta M, Papassotiriou I, Dimitriadis G, Dimopoulou I.
J Crit Care. 2015 Nov 22. pii: S0883-9441(15)00561-4.

[Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department.](#)

Casagrande I, Vendramin C, Callegari T, Vidali M, Calabresi A, Ferrandu G, Cervellin G, Cavazza M, Lippi G, Zanotti I, Negro S, Rocchetti A, Arfini C. Intern Emerg Med. **2015** Sep;10(6):725-30. – suPARnostic®

[suPAR: The unspecific marker for disease presence, severity and prognosis.](#)

Eugen-Olsen J, Giamarellos-Bourboulis EJ. Int J Antimicrob Agents. **2015** Oct 31. pii: S0924-8579(15)00360-X. Review. – suPARnostic®

[Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis.](#)

Zeng M, Chang M, Zheng H, Li B, Chen Y, He W, Huang C.
Am J Emerg Med. **2015** Nov 9. pii: S0735-6757(15)00955-9.

[Soluble urokinase plasminogen activator receptor-A valuable biomarker in systemic lupus erythematosus?](#)

Enocsson H, Sjöwall C, Wetterö J. Clin Chim Acta. 2015 Feb 19. pii: S0009-8981(15)00103-5. doi: 10.1016/j.cca.2015.02.031. Review.

[p-Cresol Affects Reactive Oxygen Species Generation, Cell Cycle Arrest, Cytotoxicity and Inflammation/Atherosclerosis-Related Modulators Production in Endothelial Cells and Mononuclear Cells.](#)

Chang MC, Chang HH, Chan CP, Yeung SY, Hsien HC, Lin BR, Yeh CY, Tseng WY, Tseng SK, Jeng JH.
PLoS One. 2014 Dec 17;9(12):e114446.

[Soluble urokinase-type plasminogen activator receptor \(suPAR\) as new biomarker of the prosthetic joint infection: Correlation with inflammatory cytokines.](#)

Galliera E, Drago L, Marazzi MG, Romanò C, Vassena C, Corsi Romanelli MM.
Clin Chim Acta. 2015 Feb 20;441:23-8. – suPARnostic®

[Host Response Biomarker in Sepsis: suPAR Detection.](#)

Giamarellos-Bourboulis EJ, Georgitsi M.
Methods Mol Biol. 2015;1237:241-6. – suPARnostic®

[Clinical evaluation of multiple inflammation biomarkers for diagnosis and prognosis for patients with systemic inflammatory response syndrome.](#)

Reichsoellner M, Raggam RB, Wagner J, Krause R, Hoenigl M.
J Clin Microbiol. 2014 Nov;52(11):4063-6. – suPARnostic®

[Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis.](#)

Okulu E, Arsan S, Akin IM, Ates C, Alan S, Kilic A, Atasay B.
J Clin Lab Anal. **2015** Sep;29(5):347-52. – suPARnostic®

[Biomarkers for Sepsis.](#)

Henriquez-Camacho C, Losa J.
Biomed Res Int. 2014;2014:547818. Review.

[Soluble Urokinase Plasminogen Activator Receptor \(suPAR\) predicts mortality in patients with Systemic Inflammatory Response Syndrome \(SIRS\).](#)

Raggam RB, Wagner J, Prüller F, Grisold A, Leitner E, Zollner-Schwetz I, Valentin T, Krause R, Hoenigl M. J Intern Med. 2014 Mar 19. – **suPARnostic®**

[Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high sensitivity c-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic hemodialysis patients?](#)

Almroth G, Lönn J, Uhlin F, Nayeri F, Brudin L, Andersson B, Hahn-Zoric M.
Scand J Immunol. 2013 May 31. – **suPARnostic®**

[Effects of acute exercise and allopurinol administration on soluble urokinase plasminogen activator receptor \(suPAR\).](#)

Sanchis-Gomar F, Bonaguri C, Pareja-Galeano H, Gomez-Cabrera MC, Candel J, Viña J, Lippi G.
Clin Lab. 2013;59(1-2):207-10. – **suPARnostic®**

[Inflammatory Markers in the Second Trimester Prior to Clinical Onset of Preeclampsia, Intrauterine Growth Restriction, and Spontaneous Preterm Birth.](#)

Haedersdal S, Salvig JD, Aabye M, Thorball CW, Ruhwald M, Ladelund S, Eugen-Olsen J, Secher NJ.
Inflammation. 2013 Mar 8. – **suPARnostic®**

[The importance of biomarkers in neonatology.](#)

Mussap M, Noto A, Cibecchini F, Fanos V. Semin Fetal Neonatal Med. 2013 Feb;18(1):56-64.

[Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.](#)

Yeh YH, Wang PH, Lin LY, Tee YT, Chou MC, Yang SF, Tsai HT. Clin Chim Acta. 2012 Oct 29;415C:138-144.

[Plasma soluble urokinase plasminogen activator receptor \(suPAR\) levels in ankylosing spondylitis.](#)

Toldi G, Szalay B, Bekő G, Kovács L, Vásárhelyi B, Balog A.
Joint Bone Spine. 2012 Sep 19. pii: S1297-319X(12)00175-3. – **suPARnostic®**

[Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor.](#)

Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I, Dimopoulou I, Mouktaroudi M, Raftogiannis M, Georgitsi M, Linner A, Adamis G, Antonopoulou A, Apostolidou E, Chrisofos M, Katsenos C, Koutelidakis I, Kotzampassi K, Koratzanis G, Koupetori M, Kritselis I, Lymberopoulou K, Mandragos K, Marioli A, Sunden-Cullberg J, Mega A, Prekates A, Routsis C, Gogos C, Treutiger CJ, Armaganidis A, Dimopoulos G. Crit Care. 2012 Aug 8;16(4):R149. – **suPARnostic®**

[Serum soluble urokinase plasminogen activator receptor \(suPAR\) in early pregnancy prior to clinical onset of preeclampsia.](#)

Odden N, Henriksen T, Mørkrid L.
Acta Obstet Gynecol Scand. 2012 Oct;91(10):1226-32. – **suPARnostic®**

[Soluble urokinase plasminogen activator receptor **suPAR** as a marker for inflammation in pediatric inflammatory bowel disease.](#)

Kolho KL, Valtonen E, Rintamäki H, Savilahti E. Scand J Gastroenterol. 2012 Jul 2.

[Immunoregulatory protein profiles of necrotizing enterocolitis versus spontaneous intestinal perforation in preterm infants.](#)

Chan KY, Leung FW, Lam HS, Tam YH, To KF, Cheung HM, Leung KT, Poon TC, Lee KH, Li K, Fok TF, Ng PC. PLoS One. 2012;7(5):e36977.

[The Prognostic Value of **suPAR** Compared to Other Inflammatory Markers in Patients with Severe Sepsis.](#)

Gustafsson A, Ljunggren L, Bodelsson M, Berkestedt I. Biomark Insights. 2012;7:39-44. – **suPARnostic**[®]

[suPAR as a prognostic biomarker in sepsis.](#)

Donadello K, Scolletta S, Covajes C, Vincent JL. BMC Med. 2012 Jan 5;10:2. Review. – **suPARnostic**[®]

[suPAR as a prognostic biomarker in sepsis.](#)

Donadello K, Scolletta S, Covajes C, Vincent JL. BMC Med. 2012 Jan 5;10:2. - **suPARnostic**[®]

[Why high **suPAR** is not super - diagnostic, prognostic and potential pathogenic properties of a novel biomarker in the ICU. \(Commentary\)](#)

Koch A, Tacke F. Crit Care. 2011 Dec 15;15(6):1020. - **suPARnostic**[®]

[Soluble urokinase plasminogen activator receptor \(**suPAR**\) levels in healthy pregnancy and preeclampsia.](#)

Toldi G, Bíró E, Szalay B, Stenczer B, Molvarec A, Rigó J, Vásárhelyi B, Bekő G. Clin Chem Lab Med. 2011 Nov;49(11):1873-6. - **suPARnostic**[®]

[The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome](#)

Yilmaz G, Köksal I, Karahan SC, Mentese A. Clin Biochem. 2011 Oct;44(14-15):1227-30. - **suPARnostic**[®]

[Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.](#)

Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F. Crit Care. 2011 Feb 16;15(1):R63.– **suPARnostic**[®]

[The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever.](#)

Yilmaz G, Mentese A, Kaya S, Uzun A, Karahan SC, Köksal I. J Clin Virol. 2011 Mar;50(3):209-11.. – **suPARnostic**[®]

[Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy.](#)

Lönnkvist MH, Theodorsson E, Holst M, Ljung T, Hellström PM.
Scand J Gastroenterol. 2011 Apr;46(4):420-7.– **suPARnostic®**

[Release of the soluble urokinase-type plasminogen activator receptor \(suPAR\) by activated neutrophils in rheumatoid arthritis.](#)

Pliyev BK, Menshikov MY.
Inflammation. 2010 Feb;33(1):1-9.

[Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency.](#)

Fevang B, Eugen-Olsen J, Yndestad A, Brosstad F, Beiske K, Aukrust P, Frøland SS.
Clin Immunol. 2009 Jun;131(3):438-46.– **suPARnostic®**

[Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology.](#)

Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J.
Clin Chem. 2006 Jul;52(7):1284-93.– **suPARnostic®**

[Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B \(MMP-9\) contribute to inflammation in gouty arthritis of the knee.](#)

Chu SC, Yang SF, Lue KH, Hsieh YS, Hsiao TY, Lu KH.
J Rheumatol. 2006 Feb;33(2):311-7.

[Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.](#)

Slot O, Brünner N, Loch H, Oxholm P, Stephens RW.
Ann Rheum Dis. 1999 Aug;58(8):488-92.

17. suPAR outside disease groups

[Seminal suPAR levels as marker of abacterial male accessory gland inflammation in hypogonadism.](#)

Milardi D, Grande G, Autilio C, Mancini F, De Marinis L, Marana R, Zuppi C, Urbani A, Pontecorvi A, Baroni S.
Protein Pept Lett. 2018 Apr 18

[Soluble urokinase-type plasminogen activator receptor is associated with signs of periodontitis in adolescents.](#)

Skottrup PD, Dahlén G, Baelum V, Lopez R. Eur J Oral Sci. 2018 May 11

[Soluble urokinase-type plasminogen activator receptor \(suPAR\) and interleukin-6 levels in hyperemesis gravidarum.](#)

Desdicioglu R, Yildirim M, Kocaoglu G, Demir Cendek B, Avcioglu G, Tas EE, Sengul O, Erel O, Yavuz AF. J Chin Med Assoc. 2017 Oct 9 [Epub]

[Resveratrol Attenuates Adriamycin-Induced Focal Segmental Glomerulosclerosis through C3aR/C5aR-Sphingosine Kinase 1 Pathway.](#)

Liu G, Wang Q, Shi Y, Peng X, Liu H, Peng Y, He L. 2017

[Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels.](#)

Gustafsson A, Ajeti V, Ljunggren L.
Biomark Insights. 2011;6:119-25. - **suPARnostic®**

[suPAR: the molecular crystal ball.](#)

Thunø M, Macho B, Eugen-Olsen J.
Dis Markers. 2009;27(3):157-72. Review.

[Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor \(uPAR/CD87\).](#)

Pliyev BK.
Mol Cell Biochem. 2009 Jan;321(1-2):111-22.

[Nanomechanical recognition of prognostic biomarker suPAR with DVD-ROM optical technology.](#)

Bache M, Bosco FG, Brøgger AL, Frøhling K, Alstrøm T, Hwu ET, Chen CH, Eugen-Olsen J, Hwang IS, Boisen A.
Nanotechnology. 2013 Nov 8;24(44):444011.- **suPARnostic®**

18.Trauma

[Soluble urokinase plasminogen activator receptor informs on the progression course after multiple injuries.](#)

Patrani M, Tsaganos T, Kotzampassi K, Paraschos M, Katsenos C, Giamarellos-Bourboulis EJ, Mandragos K.
Biomarkers. 2016 Nov;21(7):660-4. - **suPARnostic®**

[Serum Soluble Urokinase-type Plasminogen Activator Receptor as a serum marker of inflammatory response that lead to tissue damage and surgical complication.](#)

Tognoli E, Leoni M, Morelli D, Sottotetti E, Martinetti A, Signoroni S, Galeone C, Gallino G.
Wound Repair Regen. 2016 Oct 19. - **suPARnostic®**

[Soluble urokinase-type plasminogen activator levels are related to plasma cytokine levels but have low predictive value for mortality in trauma patients.](#)

Timmermans K, Vaneker M, Scheffer GJ, Maassen P, Janssen S, Kox M, Pickkers P.
J Crit Care. 2015 Jan 9. pii: S0883-9441(15)00008-8. - **suPARnostic®**

[Diagnostic and prognostic significance of suPAR in traumatic brain injury.](#)

Yu L, Wu X, Wang H, Long D, Yang J, Zhang Y. Neurol India. 2014 Sep-Oct;62(5):498-502.

[Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study.](#)

Backes Y, van der Sluijs KF, Tuip de Boer AM, Hofstra JJ, Vlaar AP, Determann RM, Knape P, Mackie DP, Schultz MJ.
Crit Care. 2011 Nov 16;15(6):R270 - **suPARnostic®**

19.Transplantation

[Soluble urokinase plasminogen activator receptor during allogeneic stem cell transplantation.](#)

Haastrop E, Andersen J, Ostrowski SR, Høyer-Hansen G, Jacobsen N, Heilmann C, Ullum H, Müller K.
Scand J Immunol. 2011 Apr;73(4):325-9. d